```
=> file caplus
FILE 'CAPLUS' ENTERED AT 14:48:41 ON 14 OCT 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 14 Oct 2008  VOL 149 ISS 16
FILE LAST UPDATED: 12 Oct 2008  (20081012/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> d que
L1                STR
```




```
Structure attributes must be viewed using STN Express query preparation.
L3          195 SEA FILE=REGISTRY SSS FUL L1
L4           50 SEA FILE=CAPLUS L3


=> d l4 1-50 ibib abs hitstr

L4   ANSWER 1 OF 50  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2008:829945  CAPLUS
DOCUMENT NUMBER:          149:153074
TITLE:                    Preparation of pyridines and pyrimidines as JNK and
                          ERK kinase inhibitors
INVENTOR(S):              Belanger, David B.; Siddiqui, M. Arshad; Curran,
                          Patrick J.; Hamann, Blake; Zhao, Lianyun; Reddy,
                          Panduranga Adulla P.; Tadikonda, Praveen K.; Shipps,
                          Gerald W., Jr.; Mansoor, Umar Faruk
PATENT ASSIGNEE(S):       Schering Corporation, USA
SOURCE:                   PCT Int. Appl., 243pp.
                          CODEN: PIXXD2
```

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008082487	A2	20080710	WO 2007-US25764	20071217

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2006-876104P P 20061220
OTHER SOURCE(S): MARPAT 149:153074
GI



I



II

AB Title compds. [I; X = N, CH; Y = N, CR5; R1a = H, halo, OH, alkoxy, alkyl, (substituted) aryl, heteroaryl, amino; R2a = H, halo, alkyl, OH, alkoxy, amino; R3 = H, halo, alkyl, cycloalkyl, (substituted) aminocarbonyl, aryl, heteroaryl, amino, etc.; R4 = (substituted) aminocarbonyl, aryl, heteroaryl, heterocycloalkyl, amino, etc.; R5 = H, halo, OH, alkoxy, amino], were prepared Thus, title compound (II) (preparation outlined) inhibited JNK1 with IC50 = 4 nM.

IT 1038409-10-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyridines and pyrimidines as JNK and ERK kinase inhibitors)

RN 1038409-10-7 CAPLUS
CN 2-Pyridinecarboxamide, 6-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)



IT 1038408-88-6P 1038408-89-7P
RL: PRPH (Prophetic); RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyridines and pyrimidines as JNK and ERK kinase inhibitors)
RN 1038408-88-6 CAPLUS
CN 2-Pyridinecarboxamide, 6-[4-(3-fluorophenyl)-1H-pyrazol-1-yl]-N-[[1-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 1038408-89-7 CAPLUS
CN 2-Pyridinecarboxamide, 6-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]-N-[[1-[4-(methylsulfonyl)phenyl]-1H-pyrazol-4-yl]methyl]- (CA INDEX NAME)

PAGE 1-A





L4 ANSWER 2 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:829152 CAPLUS
DOCUMENT NUMBER: 149:153073
TITLE: Heterocyclic carboxamide derivatives as calpain inhibitors and their preparation, pharmaceutical compositions and use in the treatment of diseases
INVENTOR(S): Kling, Andreas; Hornberger, Wilfried; Mack, Helmut; Moeller, Achim; Nimmrich, Volker; Seemann, Dietmar; Lubisch, Wilfried
PATENT ASSIGNEE(S): Abbott G.m.b.H. & Co. K.-G., Germany
SOURCE: PCT Int. Appl., 145pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008080969	A1	20080710	WO 2007-EP64617	20071228
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20080234329	A1	20080925	US 2008-70941	20080222
US 20080234330	A1	20080925	US 2008-72065	20080222
PRIORITY APPLN. INFO.:			EP 2006-127369 A	20061229
			WO 2007-EP64617 A1	20071228

OTHER SOURCE(S): MARPAT 149:153073
GI



I



II

AB The invention relates to carboxamide derivs. of formula I and their use for the manufacture of a medicament. The carboxamide compds. are inhibitors of calpain (calcium dependent cysteine proteases). The invention therefore also relates to the use of these carboxamide compds. for treating a disorder associated with an elevated calpain activity. Compds. of formula I wherein , R1 is H, (un)substituted C1-10 alkyl, (un)substituted C2-10 alkenyl, (un)substituted C2-10 alkynyl, C3-7 (hetero)cycloalkyl, C3-7 (hetero)cycloalkyl-C1-4 alkyl, etc.; R2 is H, (un)substituted C1-10 alkyl, (un)substituted C1-10 alkoxy, (un)substituted C2-10 alkenyl, (un)substituted C2-10 alkynyl, (un)substituted C3-7 (hetero)cycloalkyl, etc.; R3a and R3b are independently OH and C1-4 alkoxy; R3aR3b may taken together with the carbon attached to form C=O; X is H, CO2H and derivs., CONH2 and derivs., CONH-C1-6 alkyl and derivs. and CONH-NH2 and derivs.; Y is a divalent, (un)substituted aromatic or (un)substituted 6-membered heteroarom. radical; Y is a divalent, (un)substituted aromatic or (un)substituted 6-membered heteroarom. radical; W is (un)substituted imidazolyl and (un)substituted pyrazolyl; W and R2 may take together to form (un)substituted heterobi- or heterotricyclic radical; and their tautomers, prodrugs and pharmaceutically suitable salts thereof, are claimed. Example compound II was prepared via amidation of 2-(4-phenyl-1H-imidazol-1-yl)pyridine-3-carboxylic acid with 3-amino-2-hydroxyheptanamide; the resulting N-[1-(2-amino-1-hydroxy-2-oxoethyl)pentyl]-2-(4-phenyl-1H-imidazol-1-yl)pyridine-3-carboxamide underwent oxidation to give II. All the invention compds. were evaluated for their calpain inhibitory activity. From the assay, it was determined that II exhibited the Ki values of ≤ 40 nM.

IT 1037826-41-7P, N-[1-[Amino(oxo)acetyl]pentyl]-2-(4-phenyl-1H-pyrazol-1-yl)nicotinamide 1037826-42-8P, N-(3-Amino-1-benzyl-2,3-dioxopropyl)-2-(4-phenyl-1H-pyrazol-1-yl)nicotinamide 1037827-46-5P, N-[3-Amino-2,3-dioxo-1-(phenylmethyl)propyl]-2-[4-(2-fluorophenyl)-1H-pyrazol-1-yl]pyridine-3-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocyclic carboxamide derivs. as calpain inhibitors useful in the treatment of diseases)

RN 1037826-41-7 CAPLUS
CN INDEX NAME NOT YET ASSIGNED



RN 1037826-42-8 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-amino-2,3-dioxo-1-(phenylmethyl)propyl]-2-(4-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 1037827-46-5 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-amino-2,3-dioxo-1-(phenylmethyl)propyl]-2-[4-(2-fluorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



IT 1037828-51-5P, N-[1-(2-Amino-1-hydroxy-2-oxoethyl)pentyl]-2-(4-phenyl-1H-pyrazol-1-yl)pyridine-3-carboxamide 1037828-52-6P, N-[3-Amino-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-2-(4-phenyl-1H-pyrazol-1-yl)pyridine-3-carboxamide
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of heterocyclic carboxamide derivs. as calpain inhibitors useful in the treatment of diseases)
RN 1037828-51-5 CAPLUS

CN 3-Pyridinecarboxamide, N-[1-(2-amino-1-hydroxy-2-oxoethyl)pentyl]-2-(4-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 1037828-52-6 CAPLUS
CN 3-Pyridinecarboxamide, N-[3-amino-2-hydroxy-3-oxo-1-(phenylmethyl)propyl]-2-(4-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:500481 CAPLUS
DOCUMENT NUMBER: 148:472035
TITLE: Preparation of acylaminopyrazoles as thrombin inhibitors
INVENTOR(S): Bauser, Marcus; Buchmueller, Anja; Degenfeld, Georges; Dittrich-Wengenroth, Elke; Gerdes, Christoph; Gnoth, Mark Jean; Gottschling, Dirk; Heitmeier, Stefan; Hendrix, Martin; Koebberling, Johannes; Lang, Dieter; Rester, Ulrich; Saatmann, Uwe; Tersteegen, Adrian; Bruens, Astrid
PATENT ASSIGNEE(S): Bayer HealthCare A.-G., Germany
SOURCE: PCT Int. Appl., 96pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2008046527	A1	20080424	WO 2007-EP8657	20071005
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI,				

GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG,
KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL,
PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW,
GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
BY, KG, KZ, MD, RU, TJ, TM

DE 102006048924 A1 20080424 DE 2006-102006048924 20061017
PRIORITY APPLN. INFO.: DE 2006-102006048924A 20061017
OTHER SOURCE(S): MARPAT 148:472035
GI



I II III

AB Title compds. I [R1 = Ph, 5 or 6-membered heteroaryl; R2 = Ph, 5 or 6-membered heteroaryl; R3 = H; R4 = alkyl, alkenyl, cycloalkyl; R5 = H, halo, OH, etc.; R6 = Ph, 5 or 6-membered heteroaryl, cycloalkyl, etc.] and their pharmaceutically acceptable salts and formulations were prepared For example, coupling of amine II and 3,4-dimethoxybenzeneacetic acid afforded acylaminopyrazole III in 92% yield. In thrombin inhibition assays, 7-examples of compds. I exhibited IC50 values ranging from 0.48-34 nM.

IT 1020653-18-2P 1020653-20-6P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of acylaminopyrazoles as thrombin inhibitors)

RN 1020653-18-2 CAPLUS

CN Benzeneacetamide, α,3,4-trimethoxy-N-(1-methylethyl)-N-[2-oxo-2-[[4-phenyl-1-(2-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]- (CA INDEX NAME)



RN 1020653-20-6 CAPLUS
CN Benzeneacetamide, 4-fluoro-α-methoxy-N-(1-methylethyl)-N-[2-oxo-2-[[4-phenyl-1-(2-pyridinyl)-1H-pyrazol-3-yl]amino]ethyl]- (CA INDEX NAME)



IT 1020653-52-4P 1020653-57-9P 1020653-62-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of acylaminopyrazoles as thrombin inhibitors)
RN 1020653-52-4 CAPLUS
CN 1H-Pyrazol-3-amine, 4-phenyl-1-(2-pyridinyl)- (CA INDEX NAME)



RN 1020653-57-9 CAPLUS
CN Acetamide, 2-chloro-N-[4-phenyl-1-(2-pyridinyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



RN 1020653-62-6 CAPLUS
CN Acetamide, 2-[(1-methylethyl)amino]-N-[4-phenyl-1-(2-pyridinyl)-1H-pyrazol-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2008:239735 CAPLUS
DOCUMENT NUMBER: 148:403118
TITLE: Base-Mediated Reaction of Hydrazones and Nitroolefins with a Reversed Regioselectivity: A Novel Synthesis of 1,3,4-Trisubstituted Pyrazoles
AUTHOR(S): Deng, Xiaohu; Mani, Neelakandha S.
CORPORATE SOURCE: Johnson & Johnson Pharmaceutical Research & Development, L.L.C., San Diego, CA, 92121, USA
SOURCE: Organic Letters (2008), 10(6), 1307-1310
CODEN: ORLEF7; ISSN: 1523-7060
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:403118

AB A regioselective synthesis of 1,3,4-tri- or 1,3,4,5-tetrasubstituted pyrazoles by the reaction of hydrazones with nitroolefins is described. Mediated with strong bases such as t-BuOK, the reaction exhibits a reversed, exclusive 1,3,4-regioselectivity. Subsequent quenching with strong acids such as TFA is essential to achieve good yields. A plausible stepwise cycloaddn. reaction mechanism is proposed.

IT 1016169-44-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(regioselective synthesis of 1,3,4-tri- or 1,3,4,5-tetrasubstituted pyrazoles by base-mediated reaction of hydrazones with nitroolefins with reversed regioselectivity)

RN 1016169-44-0 CAPLUS
CN Pyridine, 2-[3-(4-chlorophenyl)-4-(4-methylphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:1300822 CAPLUS
DOCUMENT NUMBER: 147:533593
TITLE: A method for the preparation of maleimido derivatives of biomolecule labeling reactants and conjugates derived thereof
INVENTOR(S): Hovinen, Jari
PATENT ASSIGNEE(S): Wallac Oy, Finland
SOURCE: PCT Int. Appl., 31pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007128873	A1	20071115	WO 2007-FI50247	20070504

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.:

FI 2006-5291	A	20060505
US 2006-797674P	P	20060505
US 2006-842036P	P	20060905

OTHER SOURCE(S): CASREACT 147:533593; MARPAT 147:533593
GI



I



II

AB This invention relates to a new method for the preparation of chelating agents or metal chelates, particularly lanthanide(III) chelates, tethered to a maleimido function and to novel end products and intermediates produced in said method. The chelating agents are maleimido derivs. (I) where L is a linking group and X is a chelating group. The invention concerns also biomol. conjugates derived thereof. Thus, the europium(III) chelate with a bis(aminomethyl)pyridine tetraacetate derivative (II) was prepared and was reacted with Ac-CVEIDK-CONH2 to give the peptide conjugate.

IT 189805-30-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of lanthanide chelates of maleimido derivs. and their biomol. conjugates)

RN 189805-30-9 CAPLUS

CN Glycine, N,N'-[[4-[2-(4-aminophenyl)ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,1'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



IT 935687-82-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of lanthanide chelates of maleimido derivs. and their biomol. conjugates)

RN 935687-82-4 CAPLUS

CN Glycine, N,N'-[[4-[2-[4-[[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]amino]phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,1'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:770584 CAPLUS
DOCUMENT NUMBER: 148:495841
TITLE: Synthesis and general bioactivity of 4-(3,4,5-trimethoxyphenyl)pyrazoles
AUTHOR(S): Fielder, Layne M.; Smith, Stanton Q.
CORPORATE SOURCE: Department of Chemistry, Virginia Military Institute, Lexington, VA, 24450, USA
SOURCE: Journal of Undergraduate Chemistry Research (2007), 6(2), 77-80
CODEN: JUCRBV; ISSN: 1541-6003
PUBLISHER: Virginia Military Institute
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 148:495841

AB Seven new 4-(3,4,5-trimethoxyphenyl)pyrazoles have been prepared by the reaction of various monosubstituted hydrazines with a vinamidinium salt. The pyrazoles were prepared in good to excellent yield and purity under mild conditions. Several of these pyrazoles exhibited activity in the brine shrimp assay.

IT 1021424-60-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(synthesis and general bioactivity of
4-(3,4,5-trimethoxyphenyl)pyrazoles)
RN 1021424-60-1 CAPLUS
CN Pyridine, 2-[4-(3,4,5-trimethoxyphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:619866 CAPLUS
DOCUMENT NUMBER: 147:52699
TITLE: Phenoxyacetic acid derivatives as CRTH2 receptor ligands, their preparation, pharmaceutical compositions, and use in therapy
INVENTOR(S): Ulven, Trond; Frimurer, Thomas; Rist, Oeystein; Kostenis, Evi; Hoegberg, Thomas; Receveur, Jean-Marie; Grimstrup, Marie
PATENT ASSIGNEE(S): 7TM Pharma A/S, Den.
SOURCE: PCT Int. Appl., 22pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007062678	A1	20070607	WO 2005-EP12881	20051129

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: WO 2005-EP12881 20051129
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention relates to phenoxyacetic acid derivs. as CRTH2 (chemoattractant receptor-homologous mol. expressed on T helper cells type 2) receptor modulators. The invention also relates to the preparation of the compds. of the invention, pharmaceutical compns. comprising a compound of the invention together with a pharmaceutically acceptable carrier, as well as to the use of the compns. for the treatment of diseases responsive to modulation of CRTH2 receptors, particularly diseases having a significant inflammatory component, such as asthma. Ring opening and heterocyclization of chromone I with (3,5-dichloropyridin-2-yl)hydrazine gave phenol II, which underwent substitution of Et bromoacetate and hydrolysis to form phenoxyacetic acid III. The compds. of the invention, e.g., III, express IC50 values below 0.5 μM in assays for CRTH2 binding and CRTH2 antagonist function.

IT 939437-70-4P, 4-Bromo-2-[[1-(3,5-dichloropyridin-2-yl)-1H-pyrazol-4-yl]carbonyl]phenoxyacetic acid
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of phenoxyacetic acid derivs. as CRTH2 receptor ligands)

RN 939437-70-4 CAPLUS

CN Acetic acid, 2-[4-bromo-2-[[1-(3,5-dichloro-2-pyridinyl)-1H-pyrazol-4-yl]carbonyl]phenoxy]- (CA INDEX NAME)



IT 939437-68-0P, (5-Bromo-2-hydroxyphenyl)[1-(3,5-dichloropyridin-2-yl)-1H-pyrazol-4-yl]methanone 939437-69-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of phenoxyacetic acid derivs. as CRTH2 receptor ligands)

RN 939437-68-0 CAPLUS

CN Methanone, (5-bromo-2-hydroxyphenyl)[1-(3,5-dichloro-2-pyridinyl)-1H-

pyrazol-4-yl]- (CA INDEX NAME)



RN 939437-69-1 CAPLUS
CN Acetic acid, 2-[4-bromo-2-[[1-(3,5-dichloro-2-pyridinyl)-1H-pyrazol-4-yl]carbonyl]phenoxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:485399 CAPLUS
DOCUMENT NUMBER: 146:482057
TITLE: Preparation of 5-aminopyrazoles as agricultural fungicides
INVENTOR(S): Huenger, Udo
PATENT ASSIGNEE(S): Basf Aktiengesellschaft, Germany
SOURCE: PCT Int. Appl., 73pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007048733	A1	20070503	WO 2006-EP67477	20061017

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: EP 2005-23586 A 20051028
OTHER SOURCE(S): MARPAT 146:482057
GI



I II

AB Title compds. I [R1 = alkyl, haloalkyl, cycloalkyl, etc.; R2 = halo, CN, alkyl, etc.; X, Y, Z = N or CR3; R3 = H, halo, CN, etc.] were prepared For example, condensation of 2-chloro-6-hydrazinopyridine and 2-(1-oxopropyl)decanenitrile afforded aminopyrazole II in 96% yield.

IT 935859-64-6P
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); SPN (Synthetic preparation); ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 5-aminopyrazoles as agricultural fungicides)

RN 935859-64-6 CAPLUS

CN 1H-Pyrazol-5-amine, 1-(6-chloro-2-pyridinyl)-3-(3-methylbutyl)-4-(2-phenylethyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:257547 CAPLUS
DOCUMENT NUMBER: 146:316909
TITLE: Preparation of anilinopyrazoles for the treatment of diabetes
INVENTOR(S): Lowe, Derek; Shelekhin, Tatiana; Wang, Gan; Ma, Xin; Iwuagwu, Christiana; Ying, Shihong; Magnuson, Steven; Rudolph, Joachim; Koebberling, Johannes; Pernerstorfer, Josef; Mueller, Thomas; Brands, Michael; Heimbach, Dirk; Lindner, Niels
PATENT ASSIGNEE(S): Bayer Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 165pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007027842	A1	20070308	WO 2006-US33957	20060831
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
CA 2620425	A1	20070308	CA 2006-2620425	20060831
EP 1928455	A1	20080611	EP 2006-802675	20060831
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, RS				
PRIORITY APPLN. INFO.:			US 2005-713146P	P 20050831
			WO 2006-US33957	W 20060831

OTHER SOURCE(S): MARPAT 146:316909
GI



I

AB Title compds. [I; R = H, alkyl; R1 = H, (substituted) alkyl, cycloalkyl, haloalkyl, Ph, pyridyl; R2 = H, halo, (substituted) alkyl, cycloalkyl, haloalkyl, Ph, pyridyl, pyrimidyl, benzodioxolanyl; R3 = (Ph-fused) (substituted) 5-6 membered heteroaryl; R4 = alkyl, cycloalkyl, alkoxy,

haloalkyl, haloalkoxy, halo; n = 0-3; X = CO2R8, CONR5R6, SO2NHR7; R5 = H, alkyl, (substituted) PhSO2; R6 = H, alkyl; R7 = H, Me; R8 = H, alkyl; with provisos], were prepared Thus, 2-[[1-(3,6-dimethylpyrazin-2-yl)-3-ethyl-4-pyridin-3-yl-1H-pyrazol-5-yl]amino]-5-methylbenzoic acid (preparation from 3-chloro-2,5-dimethylpyrazine, 3-oxopentanenitrile, Me 2-iodo-5-methylbenzoate, and 3-pyridineboronic acid given) and other I increased insulin secretion from dispersed rat islet cells by 0.8-6.8 fold over controls.

IT 928261-71-6P 928261-73-8P 928261-74-9P
928261-75-0P 928261-89-6P 928261-96-5P
928262-54-8P 928263-28-9P 928263-30-3P
928263-32-5P 928263-33-6P 928263-34-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of anilinopyrazoles for the treatment of diabetes)

RN 928261-71-6 CAPLUS
CN Benzoic acid, 2-[[3-ethyl-1-(3-methyl-2-pyridinyl)-4-phenyl-1H-pyrazol-5-yl]amino]-5-methyl- (CA INDEX NAME)



RN 928261-73-8 CAPLUS
CN Benzoic acid, 2-[[3-ethyl-1-(3-methyl-2-pyridinyl)-4-phenyl-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 928261-74-9 CAPLUS
CN Benzoic acid, 2-[[3-ethyl-4-(3-fluorophenyl)-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 928261-75-0 CAPLUS
CN Benzoic acid, 2-[[4-(4-acetylphenyl)-3-ethyl-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 928261-89-6 CAPLUS
CN Benzoic acid, 2-[[3-ethyl-4-(3-fluorophenyl)-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]-5-methyl- (CA INDEX NAME)



RN 928261-96-5 CAPLUS
CN Benzoic acid, 2-[[4-(2-fluorophenyl)-1-(3-methyl-2-pyridinyl)-3-propyl-1H-

pyrazol-5-yl]amino]- (CA INDEX NAME)



RN 928262-54-8 CAPLUS
CN Benzoic acid, 5-cyclopropyl-2-[[4-(2-fluorophenyl)-3-methyl-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]- (CA INDEX NAME)



RN 928263-28-9 CAPLUS
CN Benzoic acid, 2-[[3-ethyl-4-(2-methoxyphenyl)-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 928263-30-3 CAPLUS
CN Benzoic acid, 2-[[3-ethyl-4-[4-(methoxymethyl)phenyl]-1-(3-methyl-2-

pyridinyl)-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 928263-32-5 CAPLUS
CN Benzoic acid, 2-[[4-(3-cyanophenyl)-3-ethyl-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 928263-33-6 CAPLUS
CN Benzoic acid, 2-[[4-(3-acetylphenyl)-3-ethyl-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)- (CA INDEX NAME)



RN 928263-34-7 CAPLUS
CN Benzoic acid, 2-[[3-ethyl-4-(4-methoxyphenyl)-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)- (CA INDEX NAME)



IT 928264-33-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of anilinopyrazoles for the treatment of diabetes)
RN 928264-33-9 CAPLUS
CN Benzoic acid, 2-[[3-ethyl-4-(2-methoxyphenyl)-1-(3-methyl-2-pyridinyl)-1H-pyrazol-5-yl]amino]-5-(trifluoromethoxy)-, methyl ester (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 10 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:247504 CAPLUS
DOCUMENT NUMBER: 146:478087
TITLE: Convenient Synthesis of Maleimido-Derivatized Lanthanide(III) Chelates and Their Use in Mercapto Group Conjugation
AUTHOR(S): Hovinen, Jari
CORPORATE SOURCE: PerkinElmer Life and Analytical Sciences, Turku, FIN-20101, Finland
SOURCE: Bioconjugate Chemistry (2007), 18(2), 597-600
CODEN: BCCHES; ISSN: 1043-1802

PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:478087

AB Simple synthesis of luminescent europium(III) and terbium(III) chelates tethered to a maleimido function is described. The method is based on the following: (i) synthesis of protected ligands tethered to a maleimido function and their purification on silica gel; (ii) deprotection by acidolysis; (iii) conversion of the deprotected ligands to the corresponding lanthanide(III) chelates by passing them through a column of strong cation exchange resin loaded with the appropriate lanthanide(III) ions. According to this procedure, large quantities of mercapto-selective biomol.-labeling reactants of high purity can be prepared

IT 189805-30-9
RL: RCT (Reactant); RACT (Reactant or reagent)
(convenient synthesis of maleimido-derivatized lanthanide(III) chelates and their use in mercapto group conjugation)

RN 189805-30-9 CAPLUS

CN Glycine, N,N'-[[4-[2-(4-aminophenyl)ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,1'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



IT 935687-82-4P 935687-84-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(convenient synthesis of maleimido-derivatized lanthanide(III) chelates and their use in mercapto group conjugation)

RN 935687-82-4 CAPLUS

CN Glycine, N,N'-[[4-[2-[4-[[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]amino]phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,1'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 935687-84-6 CAPLUS
CN Glycine, N,N'-[[4-[2-[4-[[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]amino]phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-(carboxymethyl)- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:887897 CAPLUS
DOCUMENT NUMBER: 145:293047
TITLE: Preparation of heterocyclic compounds as activators for peroxisome proliferator activated receptor δ
INVENTOR(S): Sakuma, Shogo; Mochiduki, Nobutaka; Takahashi, Rie; Hirai, Toshitake; Yamakawa, Tomio; Masui, Seiichiro
PATENT ASSIGNEE(S): Nippon Chemiphar Co., Ltd., Japan
SOURCE: PCT Int. Appl., 115pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006090920	A1	20060831	WO 2006-JP304193	20060228

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

AU 2006217682	A1	20060831	AU 2006-217682		20060228
CA 2599454	A1	20060831	CA 2006-2599454		20060228
EP 1854784	A1	20071114	EP 2006-715252		20060228

R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
BA, HR, MK, YU

MX 200710511	A	20071107	MX 2007-10511		20070828
NO 2007004738	A	20071108	NO 2007-4738		20070917
KR 2007113253	A	20071128	KR 2007-721867		20070921
IN 2007CN04285	A	20071221	IN 2007-CN4285		20070927
CN 101166720	A	20080423	CN 2006-80014554		20071029
PRIORITY APPLN. INFO.:			JP 2005-52762	A	20050228
			WO 2006-JP304193	W	20060228
			WO 2006-JP4193	W	20060228

OTHER SOURCE(S): MARPAT 145:293047
GI



I

AB The title compds. I [R1, R4 = H, alkyl, alkenyl, etc.; R2 = H; R3 = alkyl; or CR2R3 is CO, or CR2R3 is C=CR7R8; R7, R8 = H, alkyl; R5, R6 = H, alkyl, haloalkyl; X, Y = CH, N; Z = O, S; A = (un)substituted pyrazole, thiophene, furan, or pyrrole ring; B = (un)substituted alkylene; n = 0 - 5] are prepared Thus, 2-[4-[3-[3-isopropyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]propionyl]-2-methylphenoxy]-2-methylpropionic acid was prepared in a multistep process from [3-isopropyl-1-(4-trifluoromethylphenyl)-1H-pyrazol-4-yl]methanol. In an assay for the activation of peroxisome proliferator-activated receptor δ, compds. of this invention showed high activity.

IT 908250-33-9P 908250-35-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of heterocyclic compds. as activators for peroxisome proliferator-activated receptor δ)

RN 908250-33-9 CAPLUS

CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

RN 908250-35-1 CAPLUS
CN Acetic acid, 2-[2-methyl-4-[3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

IT 908250-30-6P 908250-32-8P 908250-34-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of heterocyclic compds. as activators for peroxisome proliferator-activated receptor δ)

RN 908250-30-6 CAPLUS

CN 1-Propanone, 1-(4-hydroxy-3-methylphenyl)-3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

OH

RN 908250-32-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[2-methyl-4-[3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



RN 908250-34-0 CAPLUS
CN Acetic acid, 2-[2-methyl-4-[3-[3-(1-methylethyl)-1-(5-methyl-2-pyridinyl)-1H-pyrazol-4-yl]-1-oxopropyl]phenoxy]-, ethyl ester (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



REFERENCE COUNT: 21 THERE ARE 21 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:884750 CAPLUS
DOCUMENT NUMBER: 145:293082
TITLE: Preparation of pyrazolyl substituted xanthines as antagonists of A2B receptors
INVENTOR(S): Wang, Guoquan; Rieger, Jayson M.; Thompson, Robert D.
PATENT ASSIGNEE(S): Adenosine Therapeutics, LLC, USA
SOURCE: PCT Int. Appl., 70pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006091897	A2	20060831	WO 2006-US6746	20060227
WO 2006091897	A3	20070222		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,

GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

US 20070249598 A1 20071025 US 2006-362392 20060227
PRIORITY APPLN. INFO.: US 2005-656086P P 20050225
OTHER SOURCE(S): CASREACT 145:293082; MARPAT 145:293082
GI



I

AB Title compds. represented by the formula I [wherein R = H, (halo)alkyl, cycloalkyl, etc.; R1, R2 = independently H, (cyclo)alkyl, alkenyl, etc.; L1 = (un)substituted C, N, O, S or P, with proviso; Z = (un)substituted heteroaryl; Z1 = (un)substituted (hetero)aryl; n = 0-2; and pharmaceutically acceptable salts thereof] were prepared as A2B adenosine receptor (ARs) antagonists (no data). For example, cyclization of 6-chloronicotinoyl chloride with 5,6-diamino-1,3-dipropyluracil, and followed by reaction with hydrazine in EtOH, gave 1,3-dipropyl-8-(6-hydrazino-3-pyridyl)xanthine. I were tested for affinity with A2B receptors in HEK-293 cells. Thus, I and their pharmaceutical compns. are useful as A2B adenosine receptors antagonists for the treatment of A2B receptors mediated diseases, such as asthma, allergy immune disease, and etc.

IT 908241-89-4P 908241-90-7P 908241-91-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolyl substituted xanthines as antagonists of A2B receptors)

RN 908241-89-4 CAPLUS

CN 1H-Purine-2,6-dione, 1-cyclopropyl-3,9-dihydro-8-[6-(4-phenyl-1H-pyrazol-1-yl)-3-pyridinyl]-3-propyl- (CA INDEX NAME)



RN 908241-90-7 CAPLUS
CN 1H-Purine-2,6-dione, 1-cyclopropyl-3,9-dihydro-8-[6-[4-(4-methoxyphenyl)-1H-pyrazol-1-yl]-3-pyridinyl]-3-propyl- (CA INDEX NAME)



RN 908241-91-8 CAPLUS
CN 1H-Purine-2,6-dione, 1-cyclopropyl-3,9-dihydro-3-propyl-8-[6-[4-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]-3-pyridinyl]- (CA INDEX NAME)



L4 ANSWER 13 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:693655 CAPLUS
DOCUMENT NUMBER: 145:167214
TITLE: Antibacterial and antifungal activities of new pyrazolo[3,4-d]pyridazine derivatives. [Erratum to document cited in CA143:007682]
AUTHOR(S): Akbas, Esvet; Berber, Ismet
CORPORATE SOURCE: Organic Chemistry Division, Chemistry Department, Faculty of Arts and Sciences, Yuzuncu Yil University, Van, 65080, Turk.
SOURCE: European Journal of Medicinal Chemistry (2006), 41(7), 904
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English

AB On page 401, Abstract line 1 and Introduction line 23 and 24, the word "new" before "1H-pyrazole-3-carboxylic acids" should be omitted. Abstract should read: "Several new pyrazolo[3,4-d]pyrazole-3-carboxylic acids and various hydrazines.". Introduction should read: "As the results of these reactions were synthesized pyrazole-3-carboxylic acids [12,13]. The acids were converted into various derivs. of the pyrazole-pyridazine with different hydrazines.". On page 402, left column, starting with line 1 the text should read: "The compound 3 can easily be transformed into the corresponding acid chloride 4 and amide 5 derivs. [12] by the usual chemical procedures. Furthermore, a cold solution of the acid amide 5 in a mixture of DMF and SOCl2 was stirred at 0-5 °C for 2 h to give nitrile 6 [12] (Scheme 2) (see exptl. for details).". Refs. 12 and 13 should be added. Reference 12 should read: "E. Akbas, I. Berber, A. Sener, B. Hasanov II, Farmaco 60 (2005) 23-26.". Reference 13 should read: "A. Sener, E. Akbas, M.K. Sener, Turkish Journal of Chemical 28 (2004) 271-277.".

IT 791112-66-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, antibacterial, and antifungal activity of of pyrazolopyridazine derivs. starting from benzoyl(phenyl)furandione and hydrazines using cyclization as the key step (Erratum))

RN 791112-66-8 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 4-benzoyl-5-phenyl-1-(2-pyridinyl)- (CA INDEX NAME)



L4 ANSWER 14 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:386429 CAPLUS
DOCUMENT NUMBER: 144:432797
TITLE: Preparation of diaryl substituted pyrazoles and analogs for nonsense suppression
INVENTOR(S): Almstead, Neil; Karp, Gary M.; Wilde, Richard; Welch, Ellen; Campbell, Jeffrey A.; Ren, Hongyu; Chen, Guangming
PATENT ASSIGNEE(S): PTC Therapeutics, Inc., USA
SOURCE: PCT Int. Appl., 286 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006044502	A2	20060427	WO 2005-US36761	20051013
WO 2006044502	A3	20060803		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,

LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

AU	2005295727	A1	20060427	AU 2005-295727	20051013
AU	2005295778	A1	20060427	AU 2005-295778	20051013
CA	2583159	A1	20060427	CA 2005-2583159	20051013
CA	2583971	A1	20060427	CA 2005-2583971	20051013
EP	1799207	A2	20070627	EP 2005-804194	20051013
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
EP	1815206	A1	20070808	EP 2005-815159	20051013
	R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN	101076703	A	20071121	CN 2005-80042743	20051013
CN	101076332	A	20071121	CN 2005-80042744	20051013
JP	2008515985	T	20080515	JP 2007-536837	20051013
JP	2008515990	T	20080515	JP 2007-536865	20051013
BR	2005015995	A	20080819	BR 2005-15995	20051013
BR	2005016110	A	20080826	BR 2005-16110	20051013
MX	200704479	A	20070618	MX 2007-4479	20070412
MX	200704484	A	20070625	MX 2007-4484	20070412
KR	2007065429	A	20070622	KR 2007-710794	20070511
KR	2007067201	A	20070627	KR 2007-710767	20070511
IN	2007DN03576	A	20070831	IN 2007-DN3576	20070514
IN	2007DN03577	A	20070831	IN 2007-DN3577	20070514

PRIORITY APPLN. INFO.:	US 2004-617633P	P	20041013
	US 2004-617634P	P	20041013
	US 2004-617653P	P	20041013
	US 2004-617655P	P	20041013
	US 2004-617670P	P	20041013
	US 2004-624170P	P	20041103
	WO 2005-US36673	W	20051013
	WO 2005-US36761	W	20051013

OTHER SOURCE(S): MARPAT 144:432797

GI



I

AB The present invention relates to methods, compds., and compns. for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compds. I [A1 = C, CH, or N; V and X = N or C; W = N, C or CH; wherein at least one of V, W, or X = N, and wherein if W = N, at least one of V or X is also N; Y and Z = N, CRa, CO, CS (Ra = H, Me, NH2); R1 = carboxy, cyano, or carbonyl which is optionally substituted with alkoxy; R2 = absent or nitro; Ar1 = (un)substituted alkyl, aryl, 5-10

membered heterocyclyl; or Ar1 together with Ar2 form a ring; or Ar1 together with Ar3 form a ring; Ar2 is absent or together with Ar1 form a ring; Ar3 is absent or together with Ar1 form a ring; Ar4 is absent or is alkyl, alkoxy, thioalkyl, any of which together with A1 forms a 4-7 membered carbocycle or heterocycle] or compns. comprising I. More particularly, the present invention relates to methods, compds., and compns. for suppressing premature translation termination associated with a nonsense mutation in an mRNA. Over 470 compds. I were prepared E.g., a multi-step synthesis of 3-[1-(4-trifluoromethylphenyl)-1H-pyrrol-3-yl]benzoic acid, starting from 1-(triisopropylsilyl)pyrrole-3-boronic acid and Me 4-iodobenzoate, was given. Compds. I were tested for nonsense suppression activity from a cell-based luciferase reporter assay (data given).

IT 885016-97-7P 885016-98-8P 885017-23-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl pyrazoles and analogs for suppressing premature translation termination associated with nonsense mutation in an mRNA and useful in treating and preventing diseases-associated with nonsense mutations in an mRNA)

RN 885016-97-7 CAPLUS
CN Benzoic acid, 3-[1-(2-pyridinyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 885016-98-8 CAPLUS
CN Benzoic acid, 4-[1-(2-pyridinyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 885017-23-2 CAPLUS
CN Benzoic acid, 3-[1-[5-(trifluoromethyl)-2-pyridinyl]-1H-pyrazol-4-yl]- (CA INDEX NAME)



L4 ANSWER 15 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:169674 CAPLUS
DOCUMENT NUMBER: 144:412415
TITLE: Synthesis, Pharmacology, and Structure-Activity Relationships of Novel Imidazolones and Pyrrolones as Modulators of GABAA Receptors
AUTHOR(S): Grunwald, Christian; Rundfeldt, Chris; Lankau, Hans-Joachim; Arnold, Thomas; Hoefgen, Norbert; Dost, Rita; Egerland, Ute; Hofmann, Hans-Joerg; Unverferth, Klaus
CORPORATE SOURCE: elbion AG, Radebeul, D-01445, Germany
SOURCE: Journal of Medicinal Chemistry (2006), 49(6), 1855-1866
CODEN: JMCMAR; ISSN: 0022-2623
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 144:412415
AB New series of imidazolones and pyrrolones were synthesized. The compds. were tested for their anxiolytic properties due to modulation of the GABAA receptor response. Several derivs. exhibit considerable pharmacol. activity while lacking the typical side effects of benzodiazepine receptor agonists. 1-(4-Chlorophenyl)-4-morpholin-1-yl-1,5-dihydro-imidazol-2-one and 1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-one were protective in the pentylenetetrazole test in rats with oral ED50 of 27.4 and 12.8 mg/kg and TD50 (rotarod) of >500 and 265 mg/kg, resp. The min. ED in the Vogel conflict test was 3 mg/kg for both compds. Common structure-activity relationship and comparative mol. field anal. models of the various series of derivs. could be established which are in accordance with a GABAA mediated pharmacol. action. The findings fit well into an established pharmacophore model. This model is refined by an addnl. steric restriction feature.
IT 883943-17-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of amino(aryl)imidazoles and -pyrroles as GABAA receptor

agonists)
RN 883943-17-7 CAPLUS
CN Pyridine, 2-[4-(4-chlorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 76 THERE ARE 76 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:164594 CAPLUS
DOCUMENT NUMBER: 144:254143
TITLE: Preparation of 2-cyanopyrimidine derivatives as cathepsin S inhibitors for treatment of neuropathic pain
INVENTOR(S): Hart, Terance William; Hallett, Allan; Yokokawa, Fumiaki; Hirao, Hajime; Ehara, Takeru; Iwasaki, Atsuko; Sakaki, Junichi; Masuya, Keiichi; Kishida, Masashi; Irie, Osamu
PATENT ASSIGNEE(S): Novartis A.-G., Switz.; Novartis Pharma G.m.b.H.
SOURCE: PCT Int. Appl., 111 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006018284	A1	20060223	WO 2005-EP8896	20050816
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
AU 2005274319	A1	20060223	AU 2005-274319	20050816
CA 2575826	A1	20060223	CA 2005-2575826	20050816

EP 1781623	A1	20070509	EP 2005-782460		20050816
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR					
CN 101035768	A	20070912	CN 2005-80034401		20050816
JP 2008509959	T	20080403	JP 2007-526382		20050816
BR 2005014383	A	20080610	BR 2005-14383		20050816
IN 2007DN01085	A	20070803	IN 2007-DN1085		20070208
KR 2007036183	A	20070402	KR 2007-703902		20070216
MX 200701952	A	20070509	MX 2007-1952		20070216
PRIORITY APPLN. INFO.:			GB 2004-18353	A	20040817
			WO 2005-EP8896	W	20050816

OTHER SOURCE(S): MARPAT 144:254143

GI



I



II

AB The title 2-cyanopyrimidine derivs. I [wherein R1 = (cycloalkyl)alkyl, (bicycloalkyl)alkyl, etc.; R2 = halo, alkyl, (un)substituted aryl, etc.; R3 = H, halo, (un)substituted Ph, pyridyl, etc.; X = O, NH, S, etc.], or tautomers, or salts thereof were prepared For example, the compound II was prepared in a multi-step synthesis. I are useful as inhibitors of cathepsin S for the treatment of neuropathic pain (no data). A formulation containing I as an active ingredient was also described.

IT 877125-72-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of 2-cyanopyrimidine derivs. as cathepsin S inhibitors for treatment of neuropathic pain)

RN 877125-72-9 CAPLUS

CN 1H-Pyrazol-5-amine, 4-phenyl-1-(2-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1354392 CAPLUS
DOCUMENT NUMBER: 144:88317
TITLE: Preparation of heterocycle-containing alkynyl derivatives as modulators of metabotropic glutamate receptors
INVENTOR(S): Bessis, Anne-Sophie; Bolea, Christelle; Bonnet, Beatrice; Epping-Jordan, Mark; Poirier, Nicholas; Poli, Sonia-Maria; Rocher, Jean-Philippe; Thollon, Yves
PATENT ASSIGNEE(S): Addex Pharmaceuticals SA, Switz.
SOURCE: PCT Int. Appl., 308 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123703	A2	20051229	WO 2005-IB2390	20050617
WO 2005123703	A3	20061012		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005254808	A1	20051229	AU 2005-254808	20050617
CA 2570987	A1	20051229	CA 2005-2570987	20050617
EP 1765795	A2	20070328	EP 2005-766895	20050617
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
CN 101001846	A	20070718	CN 2005-80026025	20050617
BR 2005011072	A	20071127	BR 2005-11072	20050617
JP 2008502674	T	20080131	JP 2007-516076	20050617
MX 2006PA14721	A	20070622	MX 2006-PA14721	20061214
IN 2006CN04639	A	20070629	IN 2006-CN4639	20061218
KR 2007054624	A	20070529	KR 2007-700847	20070112
NO 2007000288	A	20070116	NO 2007-288	20070116

PRIORITY APPLN. INFO.: GB 2004-13605 A 20040617
WO 2005-IB2390 W 20050617
OTHER SOURCE(S): CASREACT 144:88317; MARPAT 144:88317
GI



I

AB The present invention relates to heterocycle-containing alkynyl derivs. (WC.tplbond.C(CH2)nXW' (I); variables defined below; e.g. 1-methyl-2-[4-(pyridin-2-yl)-3-butynyl]-1H-benzo[d]imidazole (shown as II)) that are modulators of metabotropic glutamate receptors - subtype 5 ("mGluR5") and are therefore useful for the treatment of central nervous system disorders as well as other disorders modulated by mGluR5 receptors. Methods of preparation are claimed and prepns. and/or characterization data for .apprx.250 examples of I are included. For example, II was prepared in 4 steps (not stated, 23, 70 and 31 % yields, resp.) starting with chlorination of (1-methyl-1H-benzimidazol-2-yl)methanol to give 2-chloromethyl-1-methyl-1H-benzimidazole, which was coupled with trimethylprop-1-ynylsilane to give 1-methyl-2-[4-(trimethylsilanyl)-3-butynyl]-1H-benzimidazole, which was deprotected to give 2-(3-butynyl)-1-methyl-1H-benzimidazole, which was coupled with 2-iodopyridine to give II. For I: W is a 5-, 6-heterocyclic ring containing a N adjacent to the ethynyl bond, which ring may optionally be fused with a 5- or 6-membered ring containing ≥1 atoms independently C, N, O and S; X = an (un)substituted C1-C6-alkyl, C1-C6-alkylhalo, C2-C6-alkynyl, C2-C6-alkenyl, O-C0-C6-alkyl, O-C1-C6-alkylhalo, O-C3-C6-alkynyl, O-C3-C6-alkenyl, O-C3-C7-cycloalkyl, C1-C6-alkyl-O, C3-C7-cycloalkyl, C3-C7-cycloalkyl-C0-C6-alkyl, et al.; W' = a 5- or 6-membered ring containing ≥1 atoms = C, N, O and S, which ring may optionally be fused with a 5- or 6-membered ring containing ≥1 atoms = C, N, O and S; addnl. details including provisos are given in the claims. Results of a mGluR5 binding assay for >200 examples of I are tabulated; also test results of a marble burying model of anxiety in mice and Vogel conflict drinking model of anxiety in rats are discussed.

IT 872365-27-0P, 2-[4-(4-Phenyl-1H-pyrazol-1-yl)-1-butynyl]pyridine 872366-02-4P, 2-[4-[4-(4-Fluorophenyl)-1H-pyrazol-1-yl]-1-butynyl]pyridine 872366-09-1P, 2-[4-[4-(o-Tolyl)-1H-pyrazol-1-yl]-1-butynyl]pyridine 872366-15-9P, 2-(Fluoromethyl)-6-[4-[4-(o-tolyl)-1H-pyrazol-1-yl]-1-butynyl]pyridine 872366-17-1P, 2-(Fluoromethyl)-6-[4-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]-1-butynyl]pyridine 872367-17-4P, 2-[4-(3-Methyl-4-phenyl-1H-pyrazol-1-yl)-1-butynyl]pyridine 872367-18-5P, 2-[4-(5-Methyl-4-phenyl-1H-pyrazol-1-yl)-1-butynyl]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(drug candidate; preparation of heterocycle-containing alkynyl derivs. as modulators of metabotropic glutamate receptors)

RN 872365-27-0 CAPLUS
CN Pyridine, 2-[4-(4-phenyl-1H-pyrazol-1-yl)-1-butyn-1-yl]- (CA INDEX NAME)



Ph

RN 872366-02-4 CAPLUS
CN Pyridine, 2-[4-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]-1-butyn-1-yl]- (CA INDEX NAME)



RN 872366-09-1 CAPLUS
CN Pyridine, 2-[4-[4-(2-methylphenyl)-1H-pyrazol-1-yl]-1-butyn-1-yl]- (CA INDEX NAME)



RN 872366-15-9 CAPLUS
CN Pyridine, 2-(fluoromethyl)-6-[4-[4-(2-methylphenyl)-1H-pyrazol-1-yl]-1-butyn-1-yl]- (CA INDEX NAME)



RN 872366-17-1 CAPLUS
CN Pyridine, 2-(fluoromethyl)-6-[4-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]-1-butyn-1-yl]- (CA INDEX NAME)



RN 872367-17-4 CAPLUS
CN Pyridine, 2-[4-(3-methyl-4-phenyl-1H-pyrazol-1-yl)-1-butyn-1-yl]- (CA INDEX NAME)



RN 872367-18-5 CAPLUS
CN Pyridine, 2-[4-(5-methyl-4-phenyl-1H-pyrazol-1-yl)-1-butyn-1-yl]- (CA INDEX NAME)



L4 ANSWER 18 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:1289898 CAPLUS
DOCUMENT NUMBER: 144:36334
TITLE: Preparation of phenyl benzoyl pyrazoles as CRTH2 receptor ligands
INVENTOR(S): Ulven, Trond; Frimurer, Thomas; Rist, Oeystein; Kostenis, Evi; Hoegberg, Thomas; Receveur, Jean-Marie; Grimstrup, Marie
PATENT ASSIGNEE(S): 7TM Pharma A/S, Den.
SOURCE: PCT Int. Appl., 115 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005115382	A1	20051208	WO 2005-EP5884	20050530
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005247110	A1	20051208	AU 2005-247110	20050530
CA 2568766	A1	20051208	CA 2005-2568766	20050530

EP 1758579	A1	20070307	EP 2005-770220		20050530
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU					
CN 1980664	A	20070613	CN 2005-80022625		20050530
BR 2005011676	A	20080108	BR 2005-11676		20050530
JP 2008500991	T	20080117	JP 2007-513846		20050530
MX 2006PA13912	A	20070718	MX 2006-PA13912		20061129
NO 2006006048	A	20070227	NO 2006-6048		20061228
KR 2007045153	A	20070502	KR 2006-727504		20061228
IN 2006CN04778	A	20070629	IN 2006-CN4778		20061228
PRIORITY APPLN. INFO.:			GB 2004-12198	A	20040529
			GB 2004-14196	A	20040624
			GB 2004-24018	A	20041029
			WO 2005-EP5884	W	20050530

OTHER SOURCE(S): MARPAT 144:36334

GI



I

AB Title compds. I [A = carboxy, carboxy bioisostere; A1 = H, Me; Ar1 = (un)substituted heteroaryl in which the groups OCHAA1 and L2 are linked to adjacent ring atoms; Ar2-3 = heteroaryl; n = 0-1; L2-3 = divalent radical (Alk1)m-Zq-(Alk2)p; m, q, p = 0-1; Alk1-2 = alkylene which may be heteroatom substituted, etc.; Z = O, S, CO SO2, etc.; with some provisions] are prepared For instance, 4-bromo-2-((1-phenyl-1H-pyrazole-4-yl)carbonyl)phenoxyacetic acid (II) is prepared in 2 steps from (5-bromo-2-hydroxyphenyl)(1-phenyl-1H-pyrazol-4-yl)methanone and Et bromoacetate. II has an IC50 < 0.5 μM for the CRTH2 receptor. I are useful for the treatment of disease responsive to modulation of CRTH2 receptor activity, such as asthma, rhinitis, allergic airway syndrome, and allergic rhinobronchitis.

IT 870809-77-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of Ph benzoyl pyrazoles as CRTH2 receptor ligands)

RN 870809-77-1 CAPLUS

CN Acetic acid, 2-[4-bromo-2-[[1-(2-pyridinyl)-1H-pyrazol-4-yl]carbonyl]phenoxy]- (CA INDEX NAME)



IT 870811-23-7P 870811-31-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of Ph benzoyl pyrazoles as CRTH2 receptor ligands)
RN 870811-23-7 CAPLUS
CN Methanone, (5-bromo-2-hydroxyphenyl)[1-(2-pyridinyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 870811-31-7 CAPLUS
CN Acetic acid, 2-[4-bromo-2-[[1-(2-pyridinyl)-1H-pyrazol-4-yl]carbonyl]phenoxy]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:376646 CAPLUS
DOCUMENT NUMBER: 143:43822
TITLE: Palladium-catalyzed coupling of pyrazoles with 2,6-dibromopyridine
AUTHOR(S): Sun, Xiaojiao; Yu, Zhengkun; Deng, Haixia; Wu, Xiaowei; Wu, Sizhong; Dong, Jinhua
CORPORATE SOURCE: Dalian Institute of Chemical Physics, The Chinese Academy of Sciences, Dalian, Liaoning, 116023, Peop. Rep. China
SOURCE: Cuihua Xuebao (2005), 26(3), 173-174
CODEN: THHPD3; ISSN: 0253-9837
PUBLISHER: Kexue Chubanshe
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:43822

AB A number of 1H-pyrazoles (substitution patterns: H, 3-Me, 3,5-Me2, 3,4,5-Me3, 3,5-Me2-4-Bn, 3-Me-5-Ph, 3,5-Ph2, and 3,5-tert-Bu2) were reacted with 2,6-dibromopyridine and the ratio of mono- and disubstituted pyrazolylpyridines was determined in presence and absence of the Pd(OAc)2/PPh3 catalyst and in dependence of molar ratio of reactants (1:1 and 1:2.4 pyridine/pyrazole). While the 3,5-tert-Bu2-substituted pyrazole did not react al all, the other pyrazoles formed the pyrazolylpyridines with broad varying yields and with nearly exclusive formation of the mono-substituted products when the reactants are used in equimolar ratio. When pyrazoles are used in excess, mono- and disubstituted products were obtained. The use of catalyst often lowered yield and shifted product ratio to mono-substitution when pyrazoles are used in excess (exception: unsubstituted pyrazole).

IT 853748-43-3P 853748-47-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(palladium-catalyzed coupling of pyrazoles with 2,6-dibromopyridine for preparation of mono- and dipyrazolyl-substituted pyridine derivs.)

RN 853748-43-3 CAPLUS
CN Pyridine, 2-bromo-6-[3,5-dimethyl-4-(phenylmethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 853748-47-7 CAPLUS
CN Pyridine, 2,6-bis[3,5-dimethyl-4-(phenylmethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:371577 CAPLUS
DOCUMENT NUMBER: 143:43821
TITLE: Base Effect and Inhibition of Catalytic Activity in Palladium-Catalyzed N-Heteroarylation of Pyrazoles with 2,6-Dibromopyridine
AUTHOR(S): Sun, Xiaojiao; Yu, Zhengkun; Wu, Sizhong; Wen, Jing
CORPORATE SOURCE: Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Liaoning, 116023, Peop. Rep. China
SOURCE: Organometallics (2005), 24(12), 2959-2963
CODEN: ORGND7; ISSN: 0276-7333
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:43821

AB 2,6-Bis(1-pyrazolyl)pyridines were prepared by palladium-catalyzed coupling of pyrazoles with 2,6-dibromopyridine. 3-R1-4-R2-5-R3-Pyrazoles (2a-h; R1, R2, R3: a H, H, H; b H, H, Me; c Me, H, Me; d Me, Me, Me; e Me, CH2Ph, Me; f Ph, H, Me; g Ph, H, Ph; h tBu, H, tBu) undergo coupling with 2,6-dibromopyridine (1) in the presence of Pd(OAc)2/PPh3 catalyst and KOtBu or NaOtBu as a base. The reaction in a molar ratio of 1:2:base = 1:2.4:2.5 afforded the monosubstituted products 2-bromo-6-(3-R1-4-R2-5-R3-1H-pyrazol-1-yl)pyridines (3a-g) as the major products when KOtBu was used as the base, together with 69-30% of the disubstituted 2,6-bis(3-R1-4-R2-5-R3-1H-pyrazol-1-yl)pyridines (4a-f, same Rn). Without using the catalyst or using NaOtBu as the base the disubstituted compds. 4a-f were formed as the major products in yields up to 93%. Reactions of 1 and 2 in a molar ratio of 1:2:base = 1:1:1

selectively produced compds. 3 in yields up to 82% when KOtBu was used as the base. The complex from the reaction of 3 and Pd(OAc)2 did not undergo further reaction with 1 to form 4 in the presence of a base. The base effect and inhibition of catalytic activity for Pd(OAc)2 are discussed.

IT 853748-43-3P 853748-47-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of substituted 2-pyrazolyl- and 2,6-dipyrazolylpyridines by palladium-catalyzed coupling of 2,6-dibromopyridine with pyrazoles)

RN 853748-43-3 CAPLUS
CN Pyridine, 2-bromo-6-[3,5-dimethyl-4-(phenylmethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 853748-47-7 CAPLUS
CN Pyridine, 2,6-bis[3,5-dimethyl-4-(phenylmethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2005:331854 CAPLUS
DOCUMENT NUMBER: 143:7682
TITLE: Antibacterial and antifungal activities of new pyrazolo[3,4-d]pyridazine derivatives
AUTHOR(S): Akbas, Esvet; Berber, Ismet
CORPORATE SOURCE: Organic Chemistry Division, Chemistry Department, Faculty of Arts and Sciences, Yuzuncu Yil University, Van, 65080, Turk.
SOURCE: European Journal of Medicinal Chemistry (2005), 40(4), 401-405
CODEN: EJMCA5; ISSN: 0223-5234
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 143:7682

GI



I

AB Several pyrazolo[3,4-d]pyridazine derivs., e.g., I, were prepared by the reaction of two 1H-pyrazole-3-carboxylic acids and various hydrazines. The compds. were tested for antimicrobial activities against Gram-neg., Gram-pos. bacteria and fungi. Two of the tested compds. showed excellent antimicrobial activities against Gram-neg., Gram-pos. bacteria and fungi with min. inhibitory concns. in the range of 0.31 to < 0.0024 mg mL-1 .

IT 791112-66-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation, antibacterial, and antifungal activity of of pyrazolopyridazine derivs. starting from benzoyl(phenyl)furandione and hydrazines using cyclization as the key step)

RN 791112-66-8 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 4-benzoyl-5-phenyl-1-(2-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:29859 CAPLUS

DOCUMENT NUMBER: 142:430215

TITLE: Transformations of 5-amino-4-(3,4-dimethoxyphenyl)pyrazoles in the diazotization reaction

AUTHOR(S): Pavlov, I. V.; Kobrakov, K. I.; Bogza, S. L.

CORPORATE SOURCE: A. N. Kosygin Moscow State Technical University, Moscow, 119991, Russia
SOURCE: Chemistry of Heterocyclic Compounds (New York, NY, United States)(Translation of Khimiya Geterotsiklicheskikh Soedinenii) (2004), 40(7), 964-965
CODEN: CHCCAL; ISSN: 0009-3122
PUBLISHER: Kluwer Academic/Consultants Bureau
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 142:430215

AB Diazotization of 5-amino-3-(4-chlorophenyl)-1-(3,5-dichloropyridin-2-yl)-4-(3,4-dimethoxyphenyl)pyrazole in AcOH afforded via intramol. azo coupling the 1-(4-chlorophenyl)-3-(3,5-dichloropyridin-2-yl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]cinnoline while diazotization in H2SO4 in the presence of arenes (2-hydroxynaphthalene or N,N-dimethylaniline) resulted in the formation of the corresponding 5-arylazo derivs. of the starting aminopyrazole via intermol. azo coupling.

IT 851040-12-5
RL: RCT (Reactant); RACT (Reactant or reagent)
(transformations of 5-amino-4-(3,4-dimethoxyphenyl)-1-(3,5-dichloropyridin-2-yl)pyrazoles by diazotization reaction to 3-(3,5-dichloropyridin-2-yl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]cinnoline and 5-arylazo-aminopyrazole derivs.)

RN 851040-12-5 CAPLUS

CN 1H-Pyrazol-5-amine, 3-(4-chlorophenyl)-1-(3,5-dichloro-2-pyridinyl)-4-(3,4-dimethoxyphenyl)- (CA INDEX NAME)



IT 851040-14-7P 851040-15-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(transformations of 5-amino-4-(3,4-dimethoxyphenyl)-1-(3,5-dichloropyridin-2-yl)pyrazoles by diazotization reaction to 3-(3,5-dichloropyridin-2-yl)-7,8-dimethoxy-3H-pyrazolo[3,4-c]cinnoline and 5-arylazo-aminopyrazole derivs.)

RN 851040-14-7 CAPLUS

CN 2-Naphthalenol, 1-[2-[3-(4-chlorophenyl)-1-(3,5-dichloro-2-pyridinyl)-4-(3,4-dimethoxyphenyl)-1H-pyrazol-5-yl]diazenyl]- (CA INDEX NAME)



RN 851040-15-8 CAPLUS
CN Benzenamine, 4-[2-[3-(4-chlorophenyl)-1-(3,5-dichloro-2-pyridinyl)-4-(3,4-dimethoxyphenyl)-1H-pyrazol-5-yl]diazenyl]-N,N-dimethyl- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:878273 CAPLUS
DOCUMENT NUMBER: 141:366220
TITLE: Preparation of diaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
INVENTOR(S): Cosford, Nicholas D. P.; Eastman, Brian W.; Huang, Dehua; Smith, Nicholas D.; Tehrani, Lida R.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA; Essa Hu
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004089303	A2	20041021	WO 2004-US11651	20040330
WO 2004089303	A3	20050428		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004228057	A1	20041021	AU 2004-228057	20040330
CA 2520870	A1	20041021	CA 2004-2520870	20040330
EP 1613614	A2	20060111	EP 2004-750171	20040330
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				
CN 1795184	A	20060628	CN 2004-80014567	20040330
JP 2006522164	T	20060928	JP 2006-510074	20040330
IN 2005DN04191	A	20070831	IN 2005-DN4191	20050916
US 20060194807	A1	20060831	US 2005-551709	20051003
PRIORITY APPLN. INFO.:			US 2003-460094P P	20030403
			WO 2004-US11651 W	20040330
OTHER SOURCE(S):	MARPAT 141:366220			

GI



I



II

AB Title compds. represented by the formula I [wherein X, Y = independently (hetero)aryl, and at least one of X and Y is a heteroaryl with N adjacent to the position of attachment to A or B; A, B = independently (hetero)alkyl, alkylsulfonylalkyl, alkylcarbonylalkyl, etc.; W, Z = independently (un)substituted (hetero)cycloalkyl, alkyl(hetero)aryl; one of A1 and A2 is N, the other in (un)substituted C; R11 = halo, alkyl, alkoxyl, amino(di)(alkyl); and pharmaceutically acceptable salts thereof]

were prepared as modulators of metabotropic glutamate receptor-5 (mGluR5). For example, reaction of 2-(2-pyridyl)malondialdehyde with hydrazine hydrate (60%), followed by substitution with 1-bromo-3-chloro-5-fluorobenzene (45%) and coupling reaction with pyridin-3-ylboronic acid (80%), gave II. The prepared I were tested for mGluR5 inhibitory activity with IC50 value of about 2 μM in the calcium flux assay. Thus, I and their pharmaceutical compns. are useful as modulators of mGluR5 for the treatment of panic, and bipolar disorder, as well as in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, panic, and bipolar disorder, as well as in the treatment of pain, Parkinson's disease, cognitive dysfunction, epilepsy, circadian rhythm disorders, obesity, drug addiction, drug abuse, drug withdrawal and other diseases (no data).

IT 777880-83-8P 777881-01-3P 777881-25-1P
777881-29-5P 777881-33-1P 777881-94-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of diaryl pyrazole modulators of metabotropic glutamate receptor-5)

RN 777880-83-8 CAPLUS
CN Pyridine, 2-[4-[3-chloro-5-(3-pyridinyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 777881-01-3 CAPLUS
CN Pyridine, 2-[4-[3-methoxy-4-(2-pyridinyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 777881-25-1 CAPLUS
CN Pyridine, 3-[3-fluoro-5-[1-(2-pyridinyl)-1H-pyrazol-4-yl]phenyl]-4-methyl- (CA INDEX NAME)



RN 777881-29-5 CAPLUS
CN 1H-Pyrrolo[2,3-c]pyridine, 1-[3-chloro-5-[1-(2-pyridinyl)-1H-pyrazol-4-yl]phenyl]- (CA INDEX NAME)



RN 777881-33-1 CAPLUS
CN Pyridine, 2-[4-[3-fluoro-4-(2-pyridinyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 777881-94-4 CAPLUS
CN Pyridine, 2-(4-[1,1'-biphenyl]-3-yl-1H-pyrazol-1-yl)- (CA INDEX NAME)



IT 777882-02-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of diaryl pyrazole modulators of metabotropic glutamate receptor-5)
RN 777882-02-7 CAPLUS
CN Pyridine, 2-[4-(3-bromo-5-chlorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



L4 ANSWER 24 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:796496 CAPLUS
DOCUMENT NUMBER: 141:290547
TITLE: Fungicidal compositions comprising N-phenyl-N-[4-(4-pyridyl)-2-pyrimidin-2-yl]amine derivatives
INVENTOR(S): Ackerman, Peter; Stierli, Daniel; Jung, Pierre Marcel Joseph; Maienfisch, Peter; Cederbaum, Fredrik Emil Malcolm; Wenger, Jean-Frederic
PATENT ASSIGNEE(S): Syngenta Participations AG, Switz.
SOURCE: Brit. UK Pat. Appl., 112 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2399754	A	20040929	GB 2004-3967	20040223
PRIORITY APPLN. INFO.:			GB 2003-7269 A	20030328
OTHER SOURCE(S):	MARPAT 141:290547			

GI



I

AB Compns. for protecting plants, especially fungicidal compns., comprise N-phenyl-N-[4-(4-pyridyl)-2-pyrimidin-2-yl]amine derivs. (I, R1 = halo or (un)substituted alkyl, alkoxy, alkenyloxy, alkynyloxy, thioalkyl, aryl,

etc.; R2-R9 = H, (un)substituted alkyl, aryl, etc.; R10 = H, (un)substituted alkyl, alkenyl, etc.; R11 = H, C1-4 alkyl, C3-4 alkenyl, etc.; m = 0, 1, 2, or 3; n, p = 0 or 1; q = 1 or 2) or a salt thereof, together with a suitable carrier and optionally addnl. active compds. Thus, spraying 1-wk-old wheat plants 0.02% I (in a test with 7 such compds.) resulted in >70% control of fungal infection assessed 10 days after inoculation with Puccinia graminis.

IT 764698-85-3
RL: AGR (Agricultural use); BSU (Biological study, unclassified); BIOL (Biological study); USES (Uses)
(as fungicide for plant protection)

RN 764698-85-3 CAPLUS

CN 2-Pyrimidinamine, N-(3-chlorophenyl)-4-[2-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)-4-pyridinyl]- (CA INDEX NAME)



REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 25 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:654838 CAPLUS

DOCUMENT NUMBER: 141:325154

TITLE: Discovery of Novel Heteroarylazoles That Are Metabotropic Glutamate Subtype 5 Receptor Antagonists with Anxiolytic Activity

AUTHOR(S): Roppe, Jeffrey; Smith, Nicholas D.; Huang, Dehua; Tehrani, Lida; Wang, Bowei; Anderson, Jeffrey; Brodkin, Jesse; Chung, Janice; Jiang, Xiaohui; King, Christopher; Munoz, Benito; Varney, Mark A.; Prasit, Petpiboon; Cosford, Nicholas D. P.

CORPORATE SOURCE: Merck Research Laboratories, San Diego, CA, 92121, USA

SOURCE: Journal of Medicinal Chemistry (2004), 47(19), 4645-4648
CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:325154

AB The highly potent, selective, and brain-penetrant metabotropic glutamate subtype 5 (mGlu5) receptor antagonists 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile and 3-fluoro-5-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile are reported. Compound 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile is active in the rat fear-potentiated startle (FPS) model of anxiety with ED50 = 5.4 mg/kg

(po) when dosed acutely. In this model the anxiolytic effects of 3-(5-pyridin-2-yl-2H-tetrazol-2-yl)benzonitrile rapidly tolerate on repeated dosing.

IT 546141-95-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(discovery of novel heteroarylazoles that are metabotropic glutamate subtype 5 receptor antagonists with anxiolytic activity)

RN 546141-95-1 CAPLUS

CN Benzonitrile, 3-[1-(2-pyridinyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



REFERENCE COUNT: 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:596910 CAPLUS

DOCUMENT NUMBER: 141:410885

TITLE: Synthesis and some reactions of 4-benzoyl-5-phenyl-1-pyridin-2-yl-1H-pyrazole-3-carboxylic acid

AUTHOR(S): Sener, Ahmet; Akbas, Esvet; Sener, M. Kasim

CORPORATE SOURCE: Art and Science Faculty, Chemistry Department, Yuezuencue Yil University, Van, 65080, Turk.

SOURCE: Turkish Journal of Chemistry (2004), 28(3), 271-277 CODEN: TJCHE3; ISSN: 1300-0527

PUBLISHER: Scientific and Technical Research Council of Turkey

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 141:410885

AB The 1H-pyrazole-3-carboxylic acid (I), obtained from the furandione and 2-hydrazinopyridine, was decarboxylated to give 4-benzoyl-5-phenyl-1-pyridin-2-yl-pyrazole derivative Some ester derivs. of I were prepared by the Fischer esterification reactions of I with various alcs. Cyclocondensation reactions of I with Ph hydrazine or hydrazine hydrate led to the formation of derivs. of pyrazolo[3,4-d]pyridazine derivs.

IT 791112-66-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and reactions of 4-benzoyl-5-phenyl-1-pyridin-2-yl-1H-pyrazole-3-carboxylic acid)

RN 791112-66-8 CAPLUS

CN 1H-Pyrazole-3-carboxylic acid, 4-benzoyl-5-phenyl-1-(2-pyridinyl)- (CA

INDEX NAME)



IT 791112-67-9P 791112-68-0P 791112-69-1P
791112-70-4P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and reactions of 4-benzoyl-5-phenyl-1-pyridin-2-yl-1H-pyrazole-3-carboxylic acid)
RN 791112-67-9 CAPLUS
CN Methanone, phenyl[5-phenyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 791112-68-0 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 4-benzoyl-5-phenyl-1-(2-pyridinyl)-, propyl ester (CA INDEX NAME)



RN 791112-69-1 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 4-benzoyl-5-phenyl-1-(2-pyridinyl)-, methyl ester (CA INDEX NAME)



RN 791112-70-4 CAPLUS
CN 1H-Pyrazole-3-carboxylic acid, 4-benzoyl-5-phenyl-1-(2-pyridinyl)-, butyl ester (CA INDEX NAME)



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:566549 CAPLUS
DOCUMENT NUMBER: 141:123620
TITLE: Preparation of pyrazole derivatives as inhibitors of mitogen activated protein kinase-activated protein kinase-2
INVENTOR(S): Hanau, Cathleen E.; Mershon, Serena Marie; Graneto, Matthew J.; Meyers, Marvin J.; Hegde, Shridhar G.; Buchler, Ingrid P.; Wu, Kun K.; Liu, Shuang; Nacro, Kassoom
PATENT ASSIGNEE(S): Pharmacia Corporation, USA
SOURCE: PCT Int. Appl., 265 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004058176	A2	20040715	WO 2003-US40932	20031219
WO 2004058176	A3	20040916		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,

	BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2510298		A1	20040715	CA 2003-2510298		20031219
AU 2003301226		A1	20040722	AU 2003-301226		20031219
AU 2003301226		A2	20040722			
US 20040152739		A1	20040805	US 2003-742494		20031219
US 20040209897		A1	20041021	US 2003-742072		20031219
EP 1572682		A2	20050914	EP 2003-814309		20031219
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
BR 2003017525		A	20051116	BR 2003-17525		20031219
CN 1747949		A	20060315	CN 2003-80109626		20031219
JP 2006511583		T	20060406	JP 2004-563946		20031219
IN 2005CN01270		A	20070622	IN 2005-CN1270		20050615
MX 2005PA06568		A	20050922	MX 2005-PA6568		20050617
US 20080113971		A1	20080515	US 2007-958229		20071217
PRIORITY APPLN. INFO.:				US 2002-434962P	P	20021220
				US 2003-742494	A1	20031219
				WO 2003-US40932	W	20031219

OTHER SOURCE(S): MARPAT 141:123620

GI



I

AB Title compds. were prepared as inhibitors of mitogen activated protein kinase-activated protein kinase-2 (MK-2). Thus, the title compound I was prepared in a multi-step synthesis and had IC50 for MK-2 inhibition of 0.0269 μM.

IT 723339-59-1P
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazole derivs. as inhibitors of mitogen activated protein kinase-activated protein kinase-2)

RN 723339-59-1 CAPLUS

CN 4H-Pyrazolo[1,5-a][1,4]diazepin-4-one, 5,6,7,8-tetrahydro-2-[2-(4-phenyl-1H-pyrazol-1-yl)-4-pyridinyl]-, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 723339-58-0
CMF C21 H18 N6 O



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L4 ANSWER 28 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:837049 CAPLUS
DOCUMENT NUMBER: 139:337966
TITLE: Preparation of pyrazolylphenethylaminocarbonylbenzenesulfonamides and related compounds as antiinflammatories and analgesics.
INVENTOR(S): Hirano, Misato; Nakao, Kazunari; Nukui, Seiji; Yamagishi, Tatsuya
PATENT ASSIGNEE(S): Pfizer Pharmaceuticals Inc., Japan; Pfizer Inc.
SOURCE: PCT Int. Appl., 162 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003087061	A1	20031023	WO 2003-IB1277	20030402
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2482382	A1	20031023	CA 2003-2482382	20030402
AU 2003216581	A1	20031027	AU 2003-216581	20030402
EP 1495005	A1	20050112	EP 2003-712488	20030402
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK						
BR 2003009188	A	20050209	BR 2003-9188			20030402
JP 2005532291	T	20051027	JP 2003-584017			20030402
US 20040019045	A1	20040129	US 2003-409881			20030409
US 7001917	B2	20060221				
MX 2004PA09960	A	20041213	MX 2004-PA9960			20041011
PRIORITY APPLN. INFO.:			US 2002-372047P		P	20020412
			WO 2003-IB1277		W	20030402

OTHER SOURCE(S): MARPAT 139:337966
GI



I

AB Title compds. [I; R1 = H, alkyl, amino, mono- or dialkylamino, (substituted) aryl, heteroaryl; R2 = H, halo, alkyl, cycloalkyl, cycloalkenyl, aralkyl, (substituted) aryl, heteroaryl; R3 = alkyl, haloalkyl, hydroxyalkyl, (substituted) aryl, heteroaryl; A, R4 = (substituted) aryl, heteroaryl; B = alkylene; X = NH, alkylimino, O, S], were prepared for treatment of prostaglandin-mediated disease such as pain, fever, and inflammation (no data). Thus, 2-(4-hydrazinophenyl)ethanol hydrochloride and benzoyl-1,1,1-trifluoroacetone were refluxed together overnight to give 56% 2-[4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethanol. The latter was stirred with p-toluenesulfonyl isocyanate in CH2Cl2 for 30 min. to give 73% 2-[4-[5-phenyl-3-(trifluoromethyl)-1H-pyrazol-1-yl]phenyl]ethyl (4-methylphenyl)sulfonylcarbamate.

IT 616878-30-9P 616878-31-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazolylphenethylaminocarbonylbenzenesulfonamides and related compds. as antiinflammatories and analgesics)

RN 616878-30-9 CAPLUS

CN Benzenesulfonamide, 4-chloro-N-[[[2-[6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)-3-pyridinyl]ethyl]amino]carbonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

RN 616878-31-0 CAPLUS

CN 1,3-Benzenedisulfonamide, N1-[[[2-[6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)-3-pyridinyl]ethyl]amino]carbonyl]-, sodium salt (1:1) (CA INDEX NAME)



● Na

IT 616879-81-3P 616879-82-4P 616879-83-5P
616879-84-6P 616879-86-8P 616879-87-9P
616879-88-0P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazolylphenethylaminocarbonylbenzenesulfonamides and related compds. as antiinflammatories and analgesics)

RN 616879-81-3 CAPLUS
CN 3-Pyridinecarboxylic acid, 6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)-, ethyl ester (CA INDEX NAME)



RN 616879-82-4 CAPLUS
CN 3-Pyridinemethanol, 6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 616879-83-5 CAPLUS
CN 3-Pyridineacetonitrile, 6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 616879-84-6 CAPLUS
CN 3-Pyridineethanamine, 6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)- (CA INDEX NAME)



RN 616879-86-8 CAPLUS
CN Carbamic acid, [2-[6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)-3-pyridinyl]ethyl]-, phenyl ester (9CI) (CA INDEX NAME)



RN 616879-87-9 CAPLUS
CN Benzenesulfonamide, 4-chloro-N-[[[2-[6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)-3-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)



RN 616879-88-0 CAPLUS
CN 1,3-Benzenedisulfonamide, N1-[[[2-[6-(3,5-dimethyl-4-phenyl-1H-pyrazol-1-yl)-3-pyridinyl]ethyl]amino]carbonyl]- (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 29 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:491179 CAPLUS
DOCUMENT NUMBER: 139:53017
TITLE: Preparation of heteroaryl substituted pyrazole modulators of metabotropic glutamate receptor-5
INVENTOR(S): Cosford, Nicholas D. P.; Chen, Chixu; Eastman, Brian W.; Huang, Dehua; Munoz, Benito; Prasit, Petpiboon; Smith, Nicholas D.
PATENT ASSIGNEE(S): Merck & Co., Inc., USA
SOURCE: PCT Int. Appl., 131 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003051833	A2	20030626	WO 2002-US40147	20021213
WO 2003051833	A3	20031030		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2469813	A1	20030626	CA 2002-2469813	20021213
AU 2002359714	A1	20030630	AU 2002-359714	20021213
AU 2002359714	B2	20061221		
EP 1458383	A2	20040922	EP 2002-794267	20021213
EP 1458383	B1	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005516934	T	20050609	JP 2003-552720	20021213
ES 2295441	T3	20080416	ES 2002-794267	20021213
WO 2004030637	A2	20040415	WO 2003-US9717	20030331
WO 2004030637	A3	20040923		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003218462	A1	20040423	AU 2003-218462	20030331
US 20050026963	A1	20050203	US 2004-497122	20040526
PRIORITY APPLN. INFO.:			US 2001-341382P	P 20011218
			WO 2002-US31294	A 20021001
			WO 2002-US40147	W 20021213

WO 2002-US41720 A 20021213
WO 2002-US40237 A 20021216
WO 2002-US40486 A 20021217
WO 2003-US9717 W 20030331

OTHER SOURCE(S): MARPAT 139:53017

GI



I

AB Pyrazole compds. substituted directly, or by a bridge, with a heteroaryl moiety containing N adjacent to the point of connection of the heteroaryl (shown as I; variables defined below; e.g. 3-[4-(pyridin-2-yl)-1H-pyrazol-1-yl]benzonitrile), are mGluR5 modulators useful in the treatment of psychiatric and mood disorders such as, for example, schizophrenia, anxiety, depression, bipolar disorder and panic, as well as in the treatment of pain, circadian rhythm disorders, and other diseases. Compds. I have mGluR5 inhibitory activity as shown by an IC50 value of <10 μM and/or an inhibition of >30% at a concentration of 3 μM in the Ca flux assay and/or inhibition of >50% at a concentration of 100 μM in the phosphatidylinositol hydrolysis assay. For I: X and Y each independently is aryl or heteroaryl wherein at least one of X and Y is a heteroaryl with N adjacent to the position of attachment to A or B resp.; A is -C0-4-alkyl, -C0-2alkyl-SO-C0-2-alkyl-, -C0-2-alkyl-SO2-C0-2alkyl-, -C0-2-alkyl-CO-C0-2-alkyl-, -C0-2-alkyl-NR9CO-C0-2-alkyl-, -C0-2-alkyl-NR9SO2-C0-2-alkyl- or -heteroC0-4alkyl. B is -C0-4-alkyl, -C0-2-alkyl-SO-C0-2-alkyl-, -C0-2alkyl-SO2-C0-2alkyl-, -C0-2-alkyl-CO-C0-2-alkyl-, -C0-2-alkyl-NR10CO-C0-2-alkyl-, -C0-2-alkyl-NR10SO2-C0-2alkyl- or -heteroC0-4alkyl; one of A1 and A2 is N, the other is CR12; R11 and R12 is each independently halogen, -C0-6alkyl, -C0-6alkoxyl, or -N(C0-4-alkyl)(C0-4-alkyl), wherein optionally R11 and R12 are combined to form a cycloalkyl, heterocycloalkyl, aryl or heteroaryl ring fused to the pyrazole moiety; any N may be an N-oxide; addnl. details including provisos are given in the claims. Although the methods of preparation are not claimed, 15 example prepns. of I and 12 example prepns. of intermediates are included; characterization data are included for an addnl. .apprx.270 examples of I.

IT 546141-95-1P, 3-[1-(Pyridin-2-yl)-1H-pyrazol-4-yl]benzonitrile
546141-96-2P, 2-[4-(3-Chlorophenyl)-1H-pyrazol-1-yl]pyridine
546141-97-3P, 2-[4-(3-Methoxyphenyl)-1H-pyrazol-1-yl]pyridine
546142-41-0P, 2-[4-(2-Chlorophenyl)-1H-pyrazol-1-yl]pyridine
546142-42-1P, 2-[4-(3-Methylphenyl)-1H-pyrazol-1-yl]pyridine
546142-81-8P, 2-[4-[3-Fluoro-5-(pyridin-3-yloxy)phenyl]-1H-pyrazol-1-yl]pyridine 546142-93-2P,
2-[4-(4-Fluorophenyl)-1H-pyrazol-1-yl]pyridine 546142-94-3P,
4-[1-(Pyridin-2-yl)-1H-pyrazol-4-yl]benzonitrile 546142-95-4P,
2-[4-[3-(Trifluoromethyl)phenyl]-1H-pyrazol-1-yl]pyridine
546142-96-5P, 2-[4-[4-(Trifluoromethyl)phenyl]-1H-pyrazol-1-yl]pyridine 546142-98-7P,
2-[4-(3-Fluorophenyl)-1H-pyrazol-1-yl]pyridine 546142-99-8P,
2-[4-(3,5-Dichlorophenyl)-1H-pyrazol-1-yl]pyridine 546143-00-4P,
2-[4-(3,5-Difluorophenyl)-1H-pyrazol-1-yl]pyridine
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES

(Uses)
(drug candidate; preparation of heteroaryl substituted pyrazole inhibitors of metabotropic glutamate receptor-5)

RN 546141-95-1 CAPLUS
CN Benzonitrile, 3-[1-(2-pyridinyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 546141-96-2 CAPLUS
CN Pyridine, 2-[4-(3-chlorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546141-97-3 CAPLUS
CN Pyridine, 2-[4-(3-methoxyphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546142-41-0 CAPLUS
CN Pyridine, 2-[4-(2-chlorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546142-42-1 CAPLUS
CN Pyridine, 2-[4-(3-methylphenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546142-81-8 CAPLUS
CN Pyridine, 2-[4-[3-fluoro-5-(3-pyridinyloxy)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546142-93-2 CAPLUS
CN Pyridine, 2-[4-(4-fluorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546142-94-3 CAPLUS
CN Benzonitrile, 4-[1-(2-pyridinyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



RN 546142-95-4 CAPLUS
CN Pyridine, 2-[4-[3-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546142-96-5 CAPLUS
CN Pyridine, 2-[4-[4-(trifluoromethyl)phenyl]-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546142-98-7 CAPLUS
CN Pyridine, 2-[4-(3-fluorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546142-99-8 CAPLUS
CN Pyridine, 2-[4-(3,5-dichlorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



RN 546143-00-4 CAPLUS
CN Pyridine, 2-[4-(3,5-difluorophenyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



L4 ANSWER 30 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:112122 CAPLUS
DOCUMENT NUMBER: 139:239629
TITLE: CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists
AUTHOR(S): Datar, Prasanna; Desai, Prashant; Coutinho, Evans; Iyer, Krishna
CORPORATE SOURCE: Department of Pharmaceutical Chemistry, Bombay College of Pharmacy, Mumbai, 400 098, India
SOURCE: Journal of Molecular Modeling (2002), 8(10), 290-301
CODEN: JMMOFK; ISSN: 0948-5023
URL: http://link.springer.de/link/service/journals/00894/contents/02/00097/paper/s00894-002-0097-6.pdf
PUBLISHER: Springer-Verlag
DOCUMENT TYPE: Journal; (online computer file)
LANGUAGE: English
AB Two 3D-QSAR methods CoMFA and CoMSIA were applied to a set of 38 angiotensin receptor(AT1) antagonists. The conformation and alignment of mols. were obtained by a novel method consensus dynamics. The representation of biol. activity, partial charge formalism, absolute orientation of the mols. in the grid, and grid spacing were also studied for their effect on the CoMFA models. The models were thoroughly validated through trials using scrambled activities and bootstrapping. The best CoMFA model had across-validated correlation coefficient (q2) of 0.632, which improved with "region focusing" to 0.680. This model had a "predictive" r2 of 0.436 on a test series that was unique and with little representation in the training set. Although the "predictive" r2 of the best CoMSIA model, which included steric, electrostatic, and hydrogen bond acceptor fields was higher than that of the best CoMFA model, the other statistical parameters like q2, r2, F value, and s were unsatisfactory. The contour maps generated using the best CoMFA model were used to identify the structural features important for biol. activity in these compds.
IT 152713-36-5
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CoMFA and CoMSIA studies of angiotensin (AT1) receptor antagonists)
RN 152713-36-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, ethyl ester (CA INDEX NAME)



REFERENCE COUNT: 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:293632 CAPLUS
DOCUMENT NUMBER: 136:325538
TITLE: Preparation of pyrazoles for the treatment of viral diseases
INVENTOR(S): Dymock, Brian William; Jones, Philip Stephen; Merrett, John Herbert; Parratt, Martin John
PATENT ASSIGNEE(S): F. Hoffmann-La Roche Ag, Switz.
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002030907	A1	20020418	WO 2001-EP11474	20011004
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 20030018197	A1	20030123	US 2001-956656	20010920
US 6699887	B2	20040302		
CA 2423515	A1	20020418	CA 2001-2423515	20011004
AU 2002021651	A	20020422	AU 2002-21651	20011004
BR 2001014483	A	20030701	BR 2001-14483	20011004
EP 1326843	A1	20030716	EP 2001-986680	20011004
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
HU 2003002722	A2	20031229	HU 2003-2722	20011004
JP 2004511469	T	20040415	JP 2002-534293	20011004
JP 4015548	B2	20071128		
NZ 524740	A	20050930	NZ 2001-524740	20011004
CN 1680333	A	20051012	CN 2005-10008832	20011004

RU 2270832	C2	20060227	RU 2003-112610		20011004
AU 2002221651	B2	20061019	AU 2002-221651		20011004
ZA 2003002519	A	20040630	ZA 2003-2519		20030331
IN 2003CN00492	A	20050415	IN 2003-CN492		20030407
MX 2003PA03070	A	20030714	MX 2003-PA3070		20030408
NO 2003001615	A	20030523	NO 2003-1615		20030409
US 20040192752	A1	20040930	US 2004-766712		20040127
US 7183296	B2	20070227			
HK 1061021	A1	20050527	HK 2004-103975		20040603
PRIORITY APPLN. INFO.:			GB 2000-24795	A	20001010
			US 2001-956656	A3	20010920
			CN 2001-817171	A3	20011004
			WO 2001-EP11474	W	20011004

OTHER SOURCE(S): MARPAT 136:325538
GI



I

AB The title compds. [I; R1 = alkyl, cycloalkyl, aryl, etc.; R2 = aryl, (un)substituted Ph; R3 = alkyl, alkoxyalkyl; A = CH2(arylalkylamino), CH2(arylalkoxy), etc.; X = S, O] that are inhibitors of the human immunodeficiency virus reverse transcriptase enzyme which is involved in viral replication, were prepared E.g., a 3-step synthesis of pyrazole I [R1 = Ph; R2 = 3,5-Cl2C6H3; X = S; R3 = Me; A = CH2Ph] which showed IC50 of 2060 nM against HIV-1 reverse transcriptase, was given.

IT 412326-26-2P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of pyrazoles as inhibitors of the HIV reverse transcriptase)

RN 412326-26-2 CAPLUS

CN Pyridine, 2-[5-[(3,5-dichlorophenyl)thio]-3-methyl-4-(phenylmethyl)-1H-pyrazol-1-yl]- (CA INDEX NAME)



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:813020 CAPLUS
DOCUMENT NUMBER: 134:128105

TITLE: Miniature single-particle immunoassay for prostate-specific antigen in serum using recombinant Fab fragments
AUTHOR(S): Harma, Harri; Tarkkinen, Piia; Soukka, Tero; Lovgren, Timo
CORPORATE SOURCE: Department of Biotechnology, University of Turku, Turku, FIN-20520, Finland
SOURCE: Clinical Chemistry (Washington, D. C.) (2000), 46(11), 1755-1761
CODEN: CLCHAU; ISSN: 0009-9147
PUBLISHER: American Association for Clinical Chemistry
DOCUMENT TYPE: Journal
LANGUAGE: English
AB Background: Quant., miniaturized nucleic acid assays and immunoassays can be developed with single microparticles, microfluorometric detection, and intrinsically fluorescent lanthanide chelates in a multiple assay format to decrease reagent consumption, cost, and assay time. We used recombinant Fab fragments to capture and detect free and total prostate-specific antigen (PSA) from serum in a submicroliter volume single-particle immunoassay. Methods: Genetically engineered thiol-Fab or thiolated monoclonal antibodies (mAbs) were covalently attached onto uniformly sized 60-μm maleimide-activated microparticles. Free and total PSA were detected with europium- or terbium-labeled Fab fragments on a single microparticle using a microfluorometer in a time-resolved mode. Results: The detection limit of the free- and total-PSA assays (mean + 3 SD of zero calibrator) was 0.35 μg/L, with a total volume of 330 nL per particle. An excellent correlation was found in microparticle and microtiter-well assays for 21 serum samples: slopes for free and total PSA were 1.06±0.03 and 1.03±0.02, resp. (Sy/x = 0.084 and 0.057 μg/L), with intercepts of 0.013±0.018 and 0.013±0.017 μg/L (R >0.99). Furthermore, the particle-immobilized Fab fragment had a PSA binding capacity 1.5-fold higher than the intact mAb capacity on a single microparticle. Capacity, kinetics, and sensitivity of the Fab fragment and intact mAb assays in the microparticle and microtiter well formats are discussed. Conclusions: With site-specific (cysteine tail) covalent attachment of Fab fragments on a microparticle, subattomole amts. of PSA can be detected quant.
IT 321883-66-3D, europium and terbium complexes
RL: ARG (Analytical reagent use); ANST (Analytical study); USES (Uses)
(fluorescent label for mAb; miniature single-particle immunoassay for prostate-specific antigen in serum using recombinant Fab fragments)
RN 321883-66-3 CAPLUS
CN Glycine, N,N'-[[4-[2-(4-isothiocyanatophenyl)ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-(carboxymethyl)- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:124064 CAPLUS
DOCUMENT NUMBER: 132:175822
TITLE: 3,4-substituted pyrazoles for the treatment of inflammation
INVENTOR(S): Lee, Len F.; Penning, Thomas D.; Kramer, Steven W.; Talley, John J.
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: U.S., 42 pp., Cont.-in-part of U.S. 5,486,534
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6028072	A	20000222	US 1997-776090	19970609
US 5486534	A	19960123	US 1994-278297	19940721
WO 9603385	A1	19960208	WO 1995-US8788	19950720
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 1994-278297 A2 19940721
WO 1995-US8788 W 19950720
OTHER SOURCE(S): MARPAT 132:175822

AB A class of pyrazolyl compds. (Markush included) is described for use in treating inflammation and inflammation-related disorders. Compound preparation is included.

IT 259172-55-9 259173-36-9
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(pyrazole derivative preparation for treatment of inflammation and inflammation-related disorders)

RN 259172-55-9 CAPLUS

CN Pyridine, 2-[2-[4-[4-(methylsulfonyl)phenyl]-3-(4-pyridinyl)-5-(trifluoromethyl)-1H-pyrazol-1-yl]ethyl]- (CA INDEX NAME)



RN 259173-36-9 CAPLUS
CN Benzenesulfonamide, 4-[3-(4-pyridinyl)-1-[2-(2-pyridinyl)ethyl]-5-(trifluoromethyl)-1H-pyrazol-4-yl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 34 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:117030 CAPLUS
DOCUMENT NUMBER: 132:166234
TITLE: Preparation of estrogen receptor modulating pyrazoles
INVENTOR(S): Huebner, Verena D.; Lin, Xiaodong; James, Ian; Chen, Liya; Desai, Manoj; Krywult, Beata; Singh, Rajinder; Wang, Liang
PATENT ASSIGNEE(S): Chiron Corp., USA
SOURCE: PCT Int. Appl., 124 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000007996	A2	19990806	WO 1999-US17799	19990806

WO 2000007996 A3 20000831
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
AU 9954677 A 20000228 AU 1999-54677 19990806
EP 1102753 A2 20010530 EP 1999-940917 19990806
EP 1102753 B1 20070228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY
US 6291505 B1 20010918 US 1999-369747 19990806
JP 2002522422 T 20020723 JP 2000-563630 19990806
AT 355279 T 20060315 AT 1999-940917 19990806
ES 2281186 T3 20070916 ES 1999-940917 19990806
US 20020111374 A1 20020815 US 2001-954039 20010918
US 20040034081 A9 20040219
US 6727273 B2 20040427
US 20040077701 A1 20040422 US 2003-461914 20030612
US 39708 E1 20070626 US 2004-757347 20040113
PRIORITY APPLN. INFO.: US 1998-95772P P 19980807
US 1998-95773P P 19980807
US 1999-369747 A3 19990806
WO 1999-US17799 W 19990806
US 2001-954039 A1 20010918
OTHER SOURCE(S): MARPAT 132:166234

GI



I II

AB The title compds. [I and II; R1, R3 = alkyl, aryl, heteroaryl, etc.; R2 = H, halo, CN, etc.; R4 = H, CO2H, CHO, etc.] which have been found to have unexpected and surprising activity in modulating estrogen receptor activity, and therefore are useful for treating or preventing estrogen receptor-mediated disorders such as osteoporosis, breast and endometrial cancers, atherosclerosis, and Alzheimer's disease, were prepared E.g., a multi-step synthesis of II [R1 = Ph2CH; R2 = Et; R3 = 4-HOC6H4; R4 = Me], starting with 4'-methoxybutyrylphenone and 2,2-diphenylacetyl chloride, was given (no data for intermediates). Biol. data for compds. I and II were presented.

IT 258845-91-9P 258846-07-0P 258847-06-2P
258847-10-8P 258847-11-9P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of estrogen receptor modulating pyrazoles)
RN 258845-91-9 CAPLUS
CN Phenol, 4,4',4''-[1-[5-chloro-3-(trifluoromethyl)-2-pyridinyl]-1H-pyrazole-

3,4,5-triyl]tris- (9CI) (CA INDEX NAME)





RN 258846-07-0 CAPLUS
CN Phenol, 4,4',4''-[1-(2-pyridinyl)-1H-pyrazole-3,4,5-triyl]tris- (9CI) (CA INDEX NAME)

PAGE 1-A





RN 258847-06-2 CAPLUS
CN Phenol, 4,4'-[1-[6-methyl-4-(trifluoromethyl)-2-pyridinyl]-4-phenyl-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258847-10-8 CAPLUS
CN Phenol, 4,4'-[1-[5-chloro-3-(trifluoromethyl)-2-pyridinyl]-4-phenyl-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



RN 258847-11-9 CAPLUS
CN Phenol, 4,4'-[1-[3-chloro-5-(trifluoromethyl)-2-pyridinyl]-4-phenyl-1H-pyrazole-3,5-diyl]bis- (9CI) (CA INDEX NAME)



L4 ANSWER 35 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:819049 CAPLUS
DOCUMENT NUMBER: 132:64173
TITLE: Preparation of labeling reactants for fluorescent labeling of biospecific binding reactants
INVENTOR(S): Takalo, Harri; Hovinen, Jari; Mukkala, Veli-matti; Liitti, Pivi; Mikola, Heikki
PATENT ASSIGNEE(S): Wallac Oy, Finland
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 967205	A1	19991229	EP 1999-660100	19990603
EP 967205	B1	20030917		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
US 6080839	A	20000627	US 1998-104219	19980625
PRIORITY APPLN. INFO.:			US 1998-104219 A	19980625

OTHER SOURCE(S): CASREACT 132:64173; MARPAT 132:64173
GI



I



II

AB Novel pyridinediylbis(methylenenitrilo)tetrakisacetic acid labeling reactants, suitable for fluorescent labeling of biospecific binding reactants in solid-phase synthesis, were prepared The novel labeling reactants (I) [wherein A = a bivalent aromatic structure capable of absorbing light or energy and transferring the excitation energy to a lanthanide ion after the product made by solid-phase synthesis has been released from the used solid support, deprotected, and converted to a lanthanide chelate; R = -Z(G1-NH-X)G2-E; X = a transient protecting group, e.g. 2-(4-nitrophenylsulfonyl)ethoxycarbonyl, trityl, 4-methoxytrityl, 4,4'-dimethoxytrityl, BOC, Fmoc; E = a carboxylic acid, its salt, active ester (e.g. N-hydroxysuccinimido, nitrophenol, 2,4-dinitrophenol, or pentafluorophenol), or halide; Z = the bridge point; G = a bridge between A and Z; G1 = a bridge between NH and Z; G2 = a bridge between E and Z; R1 = CO2R2; R2 = alkyl or (un)substituted Ph or benzyl] are particularly useful in the labeling of small mols. Thus, II was prepared in a 4-step sequence involving (1) desilylation of Me (4-trimethylsilylethynylphenoxy)acetate (83%), (2) addition to tetra(tert-Bu) 2,2',2'',2'''-[(4-bromopyridine-2,6-diyl)bis(methylenenitrilo)]tetrakis(acetate) (75%), (3) deesterification of the phenoxyacetate with KOH (67%), and (4) amidation with α-Fmoc-lysine.HCl (56%). II was used for labeling of an estradiol derivative, incorporating four Eu(III) chelates, on a solid support (no data).

IT 253137-97-2P 253137-98-3P 253137-99-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of pyridinediylbis(methylenenitrilo)tetrakisacetic acid labeling reactants for fluorescent labeling of biospecific binding reactants in solid phase synthesis)

RN 253137-97-2 CAPLUS

CN Glycine, N,N'-[[4-[[4-(2-methoxy-2-oxoethoxy)phenyl]ethynyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 253137-98-3 CAPLUS
CN Glycine, N,N'-[[4-[2-[4-(2-methoxy-2-oxoethoxy)phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 253137-99-4 CAPLUS
CN Glycine, N,N'-[[4-[2-[4-(carboxymethoxy)phenyl]ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,1'-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



IT 253137-93-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(target compound; preparation of pyridinediylbis(methylenenitrilo)tetrakisacetic acid labeling reactants for fluorescent labeling of biospecific binding reactants in solid phase synthesis)
RN 253137-93-8 CAPLUS
CN D-Lysine, N6-[[4-[2-[1,3-bis[6-[[bis[2-(1,1-dimethylethoxy)-2-oxoethyl]amino]methyl]-2-pyridinyl]-1H-pyrazol-4-yl]ethyl]phenoxy]acetyl]-N2-[(9H-fluoren-9-ylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A





REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 36 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1999:296167 CAPLUS
DOCUMENT NUMBER: 131:44929
TITLE: Study on ferrocenes, part 6. 1,3-Dipolar cycloadditions of heterocyclic hydrazones of formylferrocene
AUTHOR(S): Abran, A.; Csampai, A.; Bocskei, Zs.; Sohar, P.
CORPORATE SOURCE: General and Inorganic Department of Chemistry, Eotvos Lorand University, Budapest, H-1518/112, Hung.
SOURCE: Tetrahedron (1999), 55(17), 5441-5448
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier Science Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 131:44929
GI



I



II

AB 1,3-Dipolar cycloaddn. reactions of ferrocenylmethyllidenehydrazones containing different heterocycles (1a-c) with some dipolarophiles resulted in new cycloadducts and condensed triazoles. For example, the reaction of I with (E)-PhCH:CHNO2 in acetonitrile over mol. sieves under argon yielded II in 87%. The reactivity of the substrates was dependent on the heterocyclic moiety. The structure of the products was determined by IR. 1H- and 13C-NMR (1-dimensional and 2D) measurements were supported by single

crystal x-ray anal.
IT 226698-83-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation via 1,3-dipolar cycloaddn. of ferrocenylmethyllidenehydrazones with various dipolarophiles)
RN 226698-83-5 CAPLUS
CN Ferrocene, [4-phenyl-1-(2-pyridinyl)-1H-pyrazol-3-yl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 18 THERE ARE 18 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 37 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1998:424244 CAPLUS
DOCUMENT NUMBER: 129:95503
ORIGINAL REFERENCE NO.: 129:19703a,19706a
TITLE: Preparation of pyrazoline compounds and use as plant disease control agent
INVENTOR(S): Taki, Toshiaki; Sato, Junichi; Kimura, Norio
PATENT ASSIGNEE(S): Sumitomo Chemical Co., Ltd., Japan; Taki, Toshiaki; Sato, Junichi; Kimura, Norio
SOURCE: PCT Int. Appl., 81 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9827084	A1	19980625	WO 1997-JP4627	19971216
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GW, HU, ID, IL, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9854129	A	19980715	AU 1998-54129	19971216
EP 967212	A1	19991229	EP 1997-947954	19971216

R: DE, FR, GB

PRIORITY APPLN. INFO.: JP 1996-335729 A 19961216
WO 1997-JP4627 W 19971216

OTHER SOURCE(S): MARPAT 129:95503

GI



I



II

AB Pyrazoline compds. represented by general formula (I; wherein R1 represents optionally substituted phenyl; R2 represents an optionally substituted hydrocarbon group; R3 represents an optionally substituted aromatic heterocyclyl; R4 and R5 are the same or different and each represents hydrogen, acyl, an optionally substituted primary or secondary alkyl; or R4 and R5 are bonded to each other to form an optionally substituted alkylene or :CR6R7; wherein R6 represents an optionally substituted hydrocarbon group, alkoxy, or mono- or dialkylamino; R7 represents H or alkyl) are prepared The compds. are used as the active ingredient of a plant disease control agent. They are useful as fungicides, in particular against mildew. Thus, 1-methylpropyl iodide was added to a mixture of 5-amino-4-(3-chlorophenyl)-1-(pyrimidin-2-yl)pyrazolin-3-one,K2CO3, and EtOH and stirred at room temperature for 72 h to give the title compound (II), which at 2.5 mg per pot controlled ≥90% Erysiphe graminis f.sp. tritici for wheat seedlings.

IT 209520-93-4P 209520-95-6P 209520-96-7P
209520-97-8P 209520-98-9P 209520-99-0P
209521-00-6P 209521-01-7P 209521-02-8P
209521-03-9P 209521-04-0P 209521-05-1P
209521-06-2P 209521-08-4P 209521-09-5P
209521-10-8P 209521-11-9P 209521-12-0P
209521-13-1P 209521-14-2P 209521-15-3P
209521-16-4P 209521-17-5P 209521-18-6P
209521-21-1P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of pyrazoline compds. as plant disease control agents)

RN 209520-93-4 CAPLUS

CN 3H-Pyrazol-3-one, 5-amino-4-(3-chlorophenyl)-1,2-dihydro-1-(2-pyridinyl)-

(CA INDEX NAME)



RN 209520-95-6 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(2-chloro-6-fluorophenyl)-1,2-dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209520-96-7 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(2-chlorophenyl)-1,2-dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209520-97-8 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1,2-dihydro-4-(3-methylphenyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209520-98-9 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1,2-dihydro-4-phenyl-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209520-99-0 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1,2-dihydro-4-(2-methoxyphenyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-00-6 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1,2-dihydro-4-(2-methylphenyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-01-7 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(2,6-dichlorophenyl)-1,2-dihydro-1-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 209521-02-8 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(4-chlorophenyl)-1,2-dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-03-9 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(3-chlorophenyl)-1,2-dihydro-1-[3-(trifluoromethyl)-2-pyridinyl]- (CA INDEX NAME)



RN 209521-04-0 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(2,6-dichlorophenyl)-1,2-dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-05-1 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1,2-dihydro-4-(4-methylphenyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-06-2 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1-(5-chloro-2-pyridinyl)-4-(2,6-dichlorophenyl)-1,2-dihydro- (CA INDEX NAME)



RN 209521-08-4 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(3-bromophenyl)-1,2-dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-09-5 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1,2-dihydro-1-(2-pyridinyl)-4-[3-(trifluoromethyl)phenyl]- (CA INDEX NAME)



RN 209521-10-8 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(3,4-difluorophenyl)-1,2-dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-11-9 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(3,4-dimethoxyphenyl)-1,2-dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-12-0 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(3,5-dichlorophenyl)-1,2-dihydro-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-13-1 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1-[4,5-bis(trifluoromethyl)-2-pyridinyl]-4-(3-chlorophenyl)-1,2-dihydro- (CA INDEX NAME)



RN 209521-14-2 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1,2-dihydro-4-(4-methoxyphenyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 209521-15-3 CAPLUS

CN 3H-Pyrazol-3-one, 5-amino-4-(3-chlorophenyl)-1-(5-chloro-2-pyridinyl)-1,2-dihydro- (CA INDEX NAME)



RN 209521-16-4 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-1-(5-bromo-2-pyridinyl)-4-(3-chlorophenyl)-1,2-dihydro- (CA INDEX NAME)



RN 209521-17-5 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(3-chlorophenyl)-1-(3-chloro-2-pyridinyl)-1,2-dihydro- (CA INDEX NAME)



RN 209521-18-6 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(3-chlorophenyl)-1-(6-chloro-2-pyridinyl)-1,2-dihydro- (CA INDEX NAME)



RN 209521-21-1 CAPLUS
CN 3H-Pyrazol-3-one, 5-amino-4-(3-chlorophenyl)-1,2-dihydro-1-(5-nitro-2-pyridinyl)- (CA INDEX NAME)



REFERENCE COUNT: 30 THERE ARE 30 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 38 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:374715 CAPLUS
DOCUMENT NUMBER: 126:350804
ORIGINAL REFERENCE NO.: 126:68079a,68082a
TITLE: Biospecific binding reactants labeled with luminescent lanthanide chelates and their use
INVENTOR(S): Rodriguez-Ubis, Juan Carlos; Takalo, Harri; Mukkala, Veli-matti
PATENT ASSIGNEE(S): Wallac Oy, Finland; Rodriguez-Ubis, Juan Carlos
SOURCE: Eur. Pat. Appl., 33 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 770610	A1	19970502	EP 1996-660056	19960909
EP 770610	B1	20050706		
R: DE, FR, GB				
US 5859215	A	19990112	US 1995-548174	19951025

PRIORITY APPLN. INFO.: US 1995-548174 A 19951025
OTHER SOURCE(S): MARPAT 126:350804
GI





I II

AB This invention relates to a detectable mol. comprising a biospecific binding reactant attached to a luminescent lanthanide chelate comprising a lanthanide ion and a chelating ligand (-O2CCH2)2NCH2-[A](-Gl)-CH2N(CHG2CO2-)(CH2CO2-) wherein -A- is a bivalent aromatic structure selected from pyridine-pyrazole compds. I, II, etc. and groups G1 or G2 are H, Cl, Br, I, CN, Ph, alkyl, alkoxy, etc., one of which is used for coupling the chelate to a biospecific binding reactant. The lanthanide ion is Eu(III), Tb(III), Dy(III) or Sm(III). The biospecific binding reactant may be selected from a group consisting of an antibody, antigen, receptor ligand, a specific binding protein, and a DNA or RNA probe.

IT 189805-29-6P 189805-30-9P 189805-36-5P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of luminescent lanthanide pyrazolediylbispyridinediyl and pyridinediylbispyrazolediyl bismethylenenitrilotetrakisacetato chelates for biospecific binding assays)

RN 189805-29-6 CAPLUS
CN Glycine, N,N'-[[4-[(4-aminophenyl)ethynyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)



RN 189805-30-9 CAPLUS
CN Glycine, N,N'-[[4-[2-(4-aminophenyl)ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-[2-(1,1-dimethylethoxy)-2-oxoethyl]-, 1,1'-bis(1,1-dimethylethyl) ester (CA INDEX NAME)



RN 189805-36-5 CAPLUS
CN Glycine, N,N'-[[4-[2-(4-aminophenyl)ethyl]-1H-pyrazole-1,3-diyl]bis(6,2-pyridinediylmethylene)]bis[N-(carboxymethyl)- (9CI) (CA INDEX NAME)



L4 ANSWER 39 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:965587 CAPLUS
DOCUMENT NUMBER: 124:175925
ORIGINAL REFERENCE NO.: 124:32623a,32626a
TITLE: Synthesis, structure and properties of pyrazole type tetrakis compounds
AUTHOR(S): Reiner, Knut; Richter, Rainer; Hauptmann, Siegfried; Becher, Jan; Hennig, Lothar
CORPORATE SOURCE: Inst. Org. Chem., Univ. Leipzig, Leipzig, D-04103, Germany
SOURCE: Tetrahedron (1995), 51(48), 13291-300
CODEN: TETRAB; ISSN: 0040-4020
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I

AB A series of pyrazole-type tetrakis compds. I (R1 = Ph, 2-pyridyl, 2-benzothiazolyl; R2 = Me, AcNH; Z = m-C6H4, p-C6H4, 2,6-pyridinediyl, 1,10-phenanthrolidinediyl) has been synthesized by reaction of aromatic or heterocyclic dialdehydes and pyrazolone derivs. Structure and tautomerism of the products were investigated by spectroscopic methods and x-ray anal. Several tetrakis compds. form inclusion complexes with solvents like alcs., ethers, and ketones in a definite ratio via hydrogen bonds.

IT 173598-23-7P 173598-24-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and inclusion reaction of tetrakis pyrazoles)

RN 173598-23-7 CAPLUS

CN 3H-Pyrazol-3-one, 4,4'-[1,3-phenylenebis[[5-hydroxy-3-methyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methylene]]bis[1,2-dihydro-5-methyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)



RN 173598-24-8 CAPLUS

CN 3H-Pyrazol-3-one, 4,4'-[1,4-phenylenebis[[5-hydroxy-3-methyl-1-(2-pyridinyl)-1H-pyrazol-4-yl]methylene]]bis[1,2-dihydro-5-methyl-2-(2-pyridinyl)- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A

L4 ANSWER 40 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:147120 CAPLUS
DOCUMENT NUMBER: 120:147120
ORIGINAL REFERENCE NO.: 120:25705a,25708a
TITLE: Pyrazolone derivatives as inhibitors of the acidic corrosion of steel
AUTHOR(S): Shein, A. B.; Pavlov, P. T.; Aitov, R. G.; Lesnov, A. E.
CORPORATE SOURCE: Perm. Gos. Univ., Perm, Russia
SOURCE: Zashchita Metallov (1993), 29(6), 940-2
CODEN: ZAMEA9; ISSN: 0044-1856
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB The pyrazolone derivs. were very effective corrosion inhibitors in hydrochloric acid solns. They can be easily synthesized, are stable and characterized by low toxicity.
IT 153231-88-0
RL: PRP (Properties)
(corrosion inhibitor, for steel, in acidic solns.)
RN 153231-88-0 CAPLUS
CN 1H-Pyrazol-5-ol, 4,4'-(phenylmethylene)bis[3-methyl-1-(2-pyridinyl)- (CA

INDEX NAME)



L4 ANSWER 41 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:134381 CAPLUS
DOCUMENT NUMBER: 120:134381
ORIGINAL REFERENCE NO.: 120:23667a,23670a
TITLE: Nonpeptide angiotensin II antagonists derived from 1H-pyrazole-5-carboxylates and 4-aryl-1H-imidazole-5-carboxylates
AUTHOR(S): Ashton, Wallace T.; Hutchins, Steven M.; Greenlee, William J.; Doss, George A.; Chang, Raymond S. L.; Lotti, Victor J.; Faust, Kristie A.; Chen, Tsing Bau; Zingaro, Gloria J.; et al.
CORPORATE SOURCE: Merck Res. Lab., Rahway, NJ, 07065, USA
SOURCE: Journal of Medicinal Chemistry (1993), 36(23), 3595-605
CODEN: JMCMAR; ISSN: 0022-2623
DOCUMENT TYPE: Journal
LANGUAGE: English
GI



I II

AB Two series of potential angiotensin II antagonists derived from carboxyl-functionalized "diazole" heterocycles have been prepared and evaluated. Initially, a limited investigation of 4-arylimidazole-5-carboxylates led to 2-n-butyl-4-(2-chlorophenyl)-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-imidazole-5-carboxylic acid (I), which was found to be a highly potent antagonist of the rabbit aorta AT1 receptor (IC50 0.55 nM). In conscious, normotensive rats, I at 0.1 mg/kg i.v. inhibited the pressor response to AII by 88%, with a duration of >6 h. More extensively studied was an isosteric series of 3-alkyl-4-[[2'-(1H-tetrazol-5-yl)biphenyl-4-

yl]methyl]-1H-pyrazole-5-carboxylates bearing aryl, alkyl, or aralkyl substituents at N1. These compds. were available in highly regioselective fashion via condensation of a substituted hydrazine hydrochloride with a 2-(methoxyimino)-4-oxoalkanoate intermediate. In vitro, the most potent pyrazolecarboxylic acids were II (R = Bu; R1 = 2,6-dichlorophenyl, 2-(trifluoromethyl)phenyl, benzyl, and phenethyl), all with IC50 values of 0.18-0.24 nM. Although less potent in the receptor assay, 3-n-propylpyrazolecarboxylic acids were at least as effective as their Bu counterpart in vivo. Several of the pyrazolecarboxylic acid derivs. demonstrated potent, long-lasting oral activity in rats. At 1 mg/kg po, the II (R = Bu, R1 = benzyl; R = Pr, R1 = 2,6-dichlorophenyl, 2,2,2-trifluoroethyl, and benzyl) analogs all gave ≥75% inhibition of the AII pressor response in the rat model, with duration of action >23 h.

IT 138733-03-6P 152713-36-5P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and angiotensin II antagonist activity of)

RN 138733-03-6 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



RN 152713-36-5 CAPLUS
CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]-, ethyl ester (CA INDEX NAME)



IT 152713-67-2P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation and cyclization of, with azide, triazole derivative from)

RN 152713-67-2 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-4-[(2'-cyano[1,1'-biphenyl]-4-yl)methyl]-1-(2-pyridinyl)-, ethyl ester (CA INDEX NAME)



L4 ANSWER 42 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:194308 CAPLUS
DOCUMENT NUMBER: 116:194308
ORIGINAL REFERENCE NO.: 116:32929a,32932a
TITLE: Preparation of 1-(2-pyridyl or -pyrimidyl)5-hydroxypyrazoles as fungicidal materials preservatives
INVENTOR(S): Sasse, Klaus; Schwamborn, Michael; Wachtler, Peter; Frie, Monika; Ludwig, Georg Wilhelm; Paulus, Wilfried; Schmitt, Hans Georg
PATENT ASSIGNEE(S): Bayer A.-G., Germany
SOURCE: Ger. Offen., 14 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4023488	A1	19920130	DE 1990-4023488	19900724
EP 469357	A1	19920205	EP 1991-111537	19910711
R: AT, CH, DE, DK, FR, GB, IT, LI, SE				
US 5175176	A	19921229	US 1991-731680	19910717
JP 04234385	A	19920824	JP 1991-203739	19910719
US 5292744	A	19940308	US 1992-929652	19920812
PRIORITY APPLN. INFO.:			DE 1990-4023488 A	19900724
			US 1991-731680 A3	19910717

OTHER SOURCE(S): MARPAT 116:194308
GI



I



II

AB Title compds. [I; R = H, (substituted) alkyl, aralkyl, alkoxy; R1 = H, (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, aralkyl, alkoxy, alkylthio, aralkoxy, aralkylthio, aryloxy, arylthio, alkoxycarbonyl, aminocarbonyl; RR1 = alk(en)ylene; R2 = halo, NO2, cyano, (substituted) alkyl, alkoxy, alkylthio, alkoxycarbonyl, aminocarbonyl; n = 0-3; X = CH, N], were prepared Thus, Et propionylacetate, 2-hydrazinopyridine, and EtOH were refluxed 3 h; KOCMe3 was added and the mixture was stirred 10 h to give title compound II. I showed min. inhibitory concns. of 5-50 mg/L against Alternaria tenuis.

IT 140397-99-5P 140398-00-1P 140398-01-2P
140398-02-3P 140398-03-4P 140398-04-5P
140398-05-6P 140398-07-8P 140398-08-9P
140398-09-0P 140398-10-3P 140398-34-1P
140398-47-6P 140398-48-7P 140398-49-8P
140398-50-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as microbicidal materials preservative)

RN 140397-99-5 CAPLUS

CN 1H-Pyrazol-5-ol, 4-(phenylmethyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-00-1 CAPLUS

CN 1H-Pyrazol-5-ol, 1-(2-pyridinyl)-4-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 140398-01-2 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(2-chlorophenyl)methyl]-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-02-3 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(2,4-dichlorophenyl)methyl]-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-03-4 CAPLUS
CN 1H-Pyrazol-5-ol, 4-(4-chlorophenyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-04-5 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(4-methylphenyl)methyl]-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-05-6 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(4-methoxyphenyl)methyl]-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-07-8 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(3-chlorophenyl)methyl]-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-08-9 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(4-bromophenyl)methyl]-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-09-0 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[(3-methylphenyl)methyl]-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-10-3 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[[4-(1,1-dimethylethyl)phenyl]methyl]-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-34-1 CAPLUS
CN 1H-Pyrazol-5-ol, 3-phenyl-4-(phenylmethyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-47-6 CAPLUS
CN 1H-Pyrazol-5-ol, 3-methyl-4-phenyl-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-48-7 CAPLUS
CN 1H-Pyrazol-5-ol, 3-methyl-4-(phenylmethyl)-1-(2-pyridinyl)- (CA INDEX NAME)



RN 140398-49-8 CAPLUS
CN 1H-Pyrazol-5-ol, 3-methyl-4-(1-phenylethyl)-1-(2-pyridinyl)- (CA INDEX

NAME)



RN 140398-50-1 CAPLUS
CN 1H-Pyrazol-5-ol, 4-[1,1'-biphenyl]-4-yl-3-methyl-1-(2-pyridinyl)- (CA INDEX NAME)



L4 ANSWER 43 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1992:106284 CAPLUS
DOCUMENT NUMBER: 116:106284
ORIGINAL REFERENCE NO.: 116:18003a,18006a
TITLE: Preparation of substituted pyrazoles, isoxazoles and isothiazoles as angiotensin II antagonists
INVENTOR(S): Allen, Eric E.; Greenlee, William J.; MacCoss, Malcolm; Ashton, Wallace T.
PATENT ASSIGNEE(S): Merck and Co., Inc., USA
SOURCE: PCT Int. Appl., 171 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9115479	A1	19911017	WO 1991-US1952	19910327
W: CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE				
CA 2079343	A1	19911001	CA 1991-2079343	19910327
EP 523141	A1	19930120	EP 1991-907490	19910327
R: CH, DE, FR, GB, IT, LI, NL				

JP 05505822 T 19930826 JP 1991-507326 19910327
PRIORITY APPLN. INFO.: US 1990-501469 A 19900330
WO 1991-US1952 W 19910327
OTHER SOURCE(S): MARPAT 116:106284
GI



I



II

AB Title compds. I [E = bond, (substituted) amino, (alkyl)thio, (alkyl)sulfinyl, (alkyl)sulfonyl), CH(OH), O, CO, K = O, S, NH, (substituted)alkylamino, etc.; X = bond, CO, O, S, NH, etc.; R1 = HO2C, HO3S, C1-4 polyfluoroalkylsulfonylamino, H2NSO2, (HO)2P(O), (substituted)heterocyclyl, etc.; R2a, R2b = H, halo, H2N, O2N, C1-4 alkyl, C1-4 alkoxy, etc.; R3a = H, halo, C1-6 alkyl, C1-6 alkoxy, etc.; R3b = H, halo, O2N, C1-6 alkyl, hydroxy-C1-4-alkyl, etc.; R6 = C1-3 alkyl, C2-5 alkenyl, C2-5 alkynyl which can be substituted, R8 = H, HO, (alkyl)(dialkyl)amino, etc.; r = 1, 2] and their salts, as angiotensin II antagonists useful in treatment of hypertension, ocular hypertension, on certain CNS disorders (no data) are prepared 5-Amino-3-butyl-1-(2-chlorophenyl)-4-[(2-tetrazol-5-ylbiphenyl-4-yl)methyl]pyrazole (preparation given) in CCl4 was diazotized to give the pyrazole derivative which was heated with NaCN in DMSO to give the nitrilepyrazole which was diluted with brine and extracted with ether to give the title pyrazole II. Pharmaceutical formulations comprising II are given.

IT 138733-03-6P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as angiotensin II inhibitor)

RN 138733-03-6 CAPLUS

CN 1H-Pyrazole-5-carboxylic acid, 3-butyl-1-(2-pyridinyl)-4-[[2'-(2H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl]methyl]- (CA INDEX NAME)



L4 ANSWER 44 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1987:133797 CAPLUS
DOCUMENT NUMBER: 106:133797
ORIGINAL REFERENCE NO.: 106:21747a,21750a
TITLE: Preparation of 1-heteroaryl-4-arylpyrazole derivatives as bactericides and fungicides
INVENTOR(S): Sasse, Klaus; Haenssler, Gerd; Schmitt, Hans Georg; Paulus, Wilfried
PATENT ASSIGNEE(S): Bayer A.-G. , Fed. Rep. Ger.
SOURCE: Ger. Offen., 22 pp.
CODEN: GWXXBX
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 3527157	A1	19870212	DE 1985-3527157	19850730
US 4772608	A	19880920	US 1986-886284	19860715
EP 212281	A1	19870304	EP 1986-109958	19860721
EP 212281	B1	19890906		
R: AT, BE, CH, DE, FR, GB, IT, LI, NL				
AT 46160	T	19890915	AT 1986-109958	19860721
DK 8603606	A	19870131	DK 1986-3606	19860729
ZA 8605649	A	19870429	ZA 1986-5649	19860729
HU 43244	A2	19871028	HU 1986-3226	19860729
JP 62033171	A	19870213	JP 1986-177885	19860730
US 4806540	A	19890221	US 1987-99928	19870923

PRIORITY APPLN. INFO.: DE 1985-3527157 A 19850730
US 1986-886284 A3 19860715
EP 1986-109958 A 19860721
OTHER SOURCE(S): CASREACT 106:133797
GI



I



II

AB Title compds. I and II (X = CH, N; R = H, alkyl; R1 = halo, OH, (un)substituted alkyl or alkoxy, NO2, etc.; R2 = H, (un)substituted alkyl, cycloalkyl, aryl, or heterocyclyl, alkoxy, alkylthio, etc.; Y = CO, SO2; n = 0, 1–5] are prepared as bactericides and fungicides. 1-Pyrid-2-yl-4-phenylpyrazolin-5-one was refluxed with Ac2O for 6 h to give I and II (R = R1 = H, R2 = Me, X = CH, Y = CO) (III and IV). III and IV were more effective in protecting rice against Pyricularia than was the standard Zineb.

IT 107360-94-1P
RL: AGR (Agricultural use); BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of, as microbicide)

RN 107360-94-1 CAPLUS

CN 1H-Pyrazol-5-ol, 4-phenyl-1-(2-pyridinyl)-, 5-acetate (CA INDEX NAME)



L4 ANSWER 45 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1971:87204 CAPLUS

DOCUMENT NUMBER: 74:87204

ORIGINAL REFERENCE NO.: 74:14157a,14160a

TITLE: Possibility of intramolecular hydrogen bonding in 1-[β-(2-pyridyl)ethyl]-5-amino(hydroxy) pyrazoles

AUTHOR(S): Alieva, S. A.; Kolodyazhnyi, Yu. V.; Garnovskii, A. D.; Osipov, O. A.; Grandberg, I. I.; Krokhina, N. F.

CORPORATE SOURCE: Rostov. -na-Donu Gos. Univ., Rostov-on-Don, USSR

SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), (9), 1255-7
CODEN: KGSSAQ; ISSN: 0132-6244

DOCUMENT TYPE: Journal

LANGUAGE: Russian

GI For diagram(s), see printed CA Issue.

AB The dipole moments of I (R = CH2Ph, R1 = Ph, R2 = 2-pyridyl, R3 = NH2), I (R = Ph, R1 = Me, R2 = 2-pyridyl, R3 = OH) and 14 other I were determined in dioxane and C6H6. The measured values agreed with those calculated on the basis of intramol. H bonds. Ir data is also discussed.

IT 19551-22-5
RL: PRP (Properties)
(dipole moment of, intramol. hydrogen bonding in relation to)

RN 19551-22-5 CAPLUS

CN Pyridine, 2-[2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)ethyl]- (8CI) (CA INDEX NAME)



L4 ANSWER 46 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1970:466516 CAPLUS
DOCUMENT NUMBER: 73:66516
ORIGINAL REFERENCE NO.: 73:10894h,10895a
TITLE: Complexes of metals with nitrogen-containing ligands. XIX. Complexes of tin tetrachloride with 1-pyridylpyrazoles and their 5-hydroxy(amino) derivatives
AUTHOR(S): Garnovskii, A. D.; Kolodyazhnyi, Yu. V.; Alieva, S. A.; Krokhina, N. F.; Grandberg, I. I.; Osipov, O. A.; Presnyakova, T. M.
CORPORATE SOURCE: Rostov.-na-Donu Gos. Univ., Rostov-on-Don, USSR
SOURCE: Zhurnal Obshchei Khimii (1970), 40(5), 1114-20
CODEN: ZOKHA4; ISSN: 0044-460X
DOCUMENT TYPE: Journal
LANGUAGE: Russian
AB From dipole moment and ir data it was concluded that 1-(2-pyridyl)pyrazole and its derivs. exist as angular isomers, in which (during complex) formation both N atoms may assume the otherwise unfavorable cis configuration. Dipole moments were tabulated from dielec. data in dioxane for 1-(pyridyl)pyrazoles with substituents selected from H, Me, PhCH2, p-H2NC6H4, p-MeC6H4, Et, Ph, and NH2; and 5-hydroxy or 5-amino derivs. of these with other substituents selected from H, Ph, Et, Bu, Me, p-MeOC6H4, and PhCH2. Several complexes of pyridylpyrazoles and (pyridylalkyl)pyrazoles with SnCl4 were prepared
IT 19541-71-0DP, Pyridine, 2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)-, tin complexes 19551-22-5DP, Pyridine, 2-[2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)ethyl]-, tin complexes
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19541-71-0 CAPLUS
CN Pyridine, 2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)- (8CI) (CA INDEX NAME)



RN 19551-22-5 CAPLUS
CN Pyridine, 2-[2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)ethyl]- (8CI) (CA INDEX NAME)



L4 ANSWER 47 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1970:110632 CAPLUS
DOCUMENT NUMBER: 72:110632
ORIGINAL REFERENCE NO.: 72:19963a,19966a
TITLE: Nitrogen-containing bisheterocyclic systems. I. Dipole moments and structure of 1-pyridylpyrazoles
AUTHOR(S): Alieva, S. A.; Kolodyazhnyi, Yu. V.; Garnovskii, A. D.; Osipov, O. A.; Grandberg, I. I.; Krokhina, N. F.
CORPORATE SOURCE: Rostov.-na-Donu Gos. Univ., Rostov-on-Don, USSR
SOURCE: Khimiya Geterotsiklicheskikh Soedinenii (1970), (1), 45-9
CODEN: KGSSAQ; ISSN: 0132-6244
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB The dipole moments of 1-pyridyl-pyrazoles and their amino derivs. were determined in C6H6 at 25° with 5 + 10-3-2 + 10-4 mole fraction. Comparison of exptl. and vectorially calculated dipole moments shows that 1-pyridyl pyrazoles, and 1-(3- or 4-pyridyl)5-aminopyrazoles have non-planar configuration; the planar angle between the pyrazole and pyridine rings was calculated For 1-(2-pyridyl)-5-aminopyrazoles the planar trans configuration is assumed due to intramol. H bonding. The following data were obtained (R, R1, R2, position attachment of pyridine ring, and planar angle between two rings given): Me, H, Me, 2, 58°; Me, H, Me, 3, 84°; Me, H, Me, 4, 0°; Pr, Et, NH2, 3, 66°; PhCH2, Ph, NH2, 3, 56°; p-MeC6H4, H, NH2, 3, 80°; Et, Me, NH2, 4, 0°; Me, H, Cl, 1, 0°; Me, H, NH2, 2, 0°; PhCH2, Ph, NH2, 2, 0°; Et, Me, NH2, 2, 0°; Pr, Et, NH2, 2, 0°; p-H2NC6H4, H, NH2, 2, 0°.[
IT 19541-71-0
RL: PRP (Properties)
(dipole moment of)
RN 19541-71-0 CAPLUS
CN Pyridine, 2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)- (8CI) (CA INDEX NAME)



L4 ANSWER 48 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1969:11624 CAPLUS
DOCUMENT NUMBER: 70:11624
ORIGINAL REFERENCE NO.: 70:2178h,2179a
TITLE: Pyrazoles. LXV. Synthesis of a series of 5-hydroxy- and 5-aminopyrazoles with nitrogen-containing functional substituents
AUTHOR(S): Grandberg, I. I.; Krokhina, N. F.; Kondrat'ev, M. N.
CORPORATE SOURCE: Mosk. S-Kh. Akad. im. Timiryazeva, Moscow, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1968), 2(7), 24-8
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB The synthesis of 5-aminopyrazoles is described. To a boiling mixture of

0.05 mole RNHNH2, 0.055 mole concentrated HCl and 10 ml. H2O was added slowly under stirring 0.05 mole R1C(:NH)CHR2CN in 20 ml. iso-PrOH and the mixture was refluxed 20 min. on a H2O bath. After adding 60 ml. concentrated HCl, refluxing was continued 2 hrs. The solvent and excess HCl were evaporated in vacuo, the residue treated with an excess of 40% KOH and if the separated oil did not crystallize it was extracted with C6H6 or ether and distilled in vacuo. The following I were prepared (R, R1, R2, % yield, and b.p./mm. given): iso-Pr, Et, Me, 73.6, 116°/8; Et, Et, Me, 90.3, 130-5°/10; Me, Et, Me, 43, 130-5°/15; Me, Me, H, 12.6, 115-18°/8; (CH2)3NMe2, Me, H, 41, 155-63°/3. A mixture of 0.05 mole RNHNH2 and 0.05 mole β-keto ester was refluxed 12 hrs. on a water bath in 50 ml. tert-BuOH, 5 ml. H2O, and 5 ml. 50% AcOH, and the solvent was evaporated in vacuo. to give the following II (R, R1, R2, % yield, and m.p. given): α-C5H4N, CH2Ph, Ph, 59, 190°; (CH2)2C5H4N-γ, CH2Ph, Ph, 37.2, 148°; β-C5H4N, CH2Ph, Ph, 82.2, 198°; γ-C5H9NMe, Ph, H, 51.8, 105°; γ-C5H9NMe, CH2Ph, Ph, 50.4, 204°. Heating 0.04 mole α-,β- or γ-pyridylhydrazine in 10 ml. iso-PrOH 1 hr. on a water-bath with 0.04 mole acetylacetone gave the following III (R, % yield, and b.p./mm. given): γ-C5H4N, 63.5, 160°/20; α-C5H4N, 60.7, 130°/18; (CH2)2C5H4N-α, 77.9, 152-5°/15; β-C5H4N, 63.5, 152-4°/18; Pyrazole carbamates (IV) were prepared by refluxing 1 hr. an equimolar mixture of methyl isocyanatocarbamate and 5-aminopyrazole in absolute HCONMe2. The following IV were prepared (R, R1, R2, % yield, and m.p. given). (CH2)2C5H4N-α, p-C6H4NHCON-HMe, H, 62, 227-8°; (CH2)2C5H4N-γ, p-C6H4HCONHMe, H, 61, 227-8°; (CH2)2C5H4N-α, CH2Ph, Ph, 58.8, 160-1°; (CH2)2-C5H4N-α, C5H11, Bu, 54.8, 76-8°.

IT 21018-65-5P 22301-80-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 21018-65-5 CAPLUS
CN Pyrazol-5-ol, 3-benzyl-4-phenyl-1-(2-pyridyl)- (8CI) (CA INDEX NAME)



RN 22301-80-0 CAPLUS
CN Urea, 1-[3-benzyl-4-phenyl-1-[2-(2-pyridyl)ethyl]pyrazol-5-yl]-3-methyl- (8CI) (CA INDEX NAME)



L4 ANSWER 49 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1968:459155 CAPLUS

DOCUMENT NUMBER: 69:59155
ORIGINAL REFERENCE NO.: 69:11059a
TITLE: Pyrazoles. LXII. The synthesis of 5-aminopyrazole series with potential physiological activity
AUTHOR(S): Grandberg, I. I.; Krokhina, N. F.
CORPORATE SOURCE: Mosk. Sel'skokhoz. Akad. im. Timiryazeva, Moscow, USSR
SOURCE: Khimiko-Farmatsevticheskii Zhurnal (1968), 2(1), 16-22
CODEN: KHFZAN; ISSN: 0023-1134
DOCUMENT TYPE: Journal
LANGUAGE: Russian
GI For diagram(s), see printed CA Issue.
AB EtCN (110 g.) in 150 cc. absolute Et2O was added carefully very slowly to 27.6 g. fine powdered Na in 150 cc. boiling Et2O, the mixture refluxed 8 hrs., and the product decomposed with 100 cc. H2O to give 27.5% RCH2C(:NH)CHRCN (I) (R = Me), b3 105-8°. Similarly, 30.8% I (R = H), 20.3% I (R = Et, and 19.3% I (R = Bu) were obtained. PhCH2CN (117 g.) was added dropwise to 11.5 g. Na in 130 cc. absolute iso-PrOH, the mixture heated 30 min. on a boiling water bath, diluted with H2O, and extracted with Et2O, Et2O distilled, and unchanged PhCH2CN distilled with steam to give 29.7% PhCH2COCHPhCN, b3 230-40°, m. 91° (iso-PrOH) [Rf 0.73 on Al2O3 thin-layer in 20:1 CHCl3-MeOH], and 15% PhCH2C(: NH)CHPhCN, b3 245-70°; Rf 0.67. Iminonitrile (0.05 mole) in 20 cc. iso-PrOH was added slowly with stirring to a boiling mixture of 0.05 mole hydrazine, 0.055 mole concentrated HCl, and 20 cc. H2O, the mixture refluxed, 60 cc. concentrated HCl added, the mixture refluxed 2 hrs. and concentrated in vacuo, and the residue treated with 40% KOH to give I given in the 1st table. [TABLE OMITTED] Similarly, p-substituted ω-cyanoacetophenones gave I (R3 = H) given in the 2nd table. II (0.1 mole) was added slowly to 20 cc. N2H4.H2O, and 4 g. Raney Ni catalyst in 200 cc. boiling iso-PrOH, and the mixture refluxed 8 hrs. to give 86% I (R1 = R2 = p-H2NC6H4, R3 = H), m. 227-9° (alc.). [TABLE OMITTED] The preliminary results of the investigation of the physiol. activity of I were pos.
IT 19541-71-0P 19551-22-5P 19551-25-8P
20456-72-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)
RN 19541-71-0 CAPLUS
CN Pyridine, 2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)- (8CI) (CA INDEX NAME)



RN 19551-22-5 CAPLUS
CN Pyridine, 2-[2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)ethyl]- (8CI) (CA INDEX NAME)



RN 19551-25-8 CAPLUS
CN Pyridine, 2-[2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)ethyl]-, tartrate (8CI) (CA INDEX NAME)

CM 1

CRN 19551-22-5
CMF C23 H22 N4



CM 2

CRN 87-69-4
CMF C4 H6 O6

Absolute stereochemistry.



RN 20456-72-8 CAPLUS
CN Pyridine, 2-(5-amino-3-benzyl-4-phenylpyrazol-1-yl)-, monohydrochloride (8CI) (CA INDEX NAME)



● HCl

L4 ANSWER 50 OF 50 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1964:45681 CAPLUS
DOCUMENT NUMBER: 60:45681
ORIGINAL REFERENCE NO.: 60:8013e-h,8014a-c
TITLE: Reactions of hydrazine derivatives. XXXIX. Addition of hydrazine and substituted hydrazines to 2-vinylpyridine
AUTHOR(S): Kost, A. N.; Suminov, S. I.; Vinogradova, E. V.; Kozler, V.
CORPORATE SOURCE: State Univ., Moscow
SOURCE: Zhurnal Obshchei Khimii (1963), 33(11), 3606-13
CODEN: ZOKHA4; ISSN: 0044-460X
DOCUMENT TYPE: Journal
LANGUAGE: Unavailable

AB cf. CA 55, 13423d; 59, 13964g. To 65 ml. 96% $N_2H_4.H_2O$ was added 25 ml. MeOH followed at 70-80° by 105 g. 2-vinylpyridine over 45-60 min.; after 8 hrs. at 80°, the mixture was left overnight and yielded 65-6.5% 2-(hydrazinoethyl)pyridine (I), b12 139-42°, b4 113-16°, n20D 1.5552, d20 1.055, which slowly decomposed even in the cold; dipicrate decomposed 145-6° (149-50° in preheated bath); di-HCl salt m. 146.5-8° p-nitrobenzylidene derivative m. 118.5-19.5°; 2-hydroxynaphthaldehyde and salicylaldehyde gave colored hydrazones; treatment with Ph isothiocyanate gave N1-phenyl-N3-[2-(2-pyridyl)ethyl]thiosemicarbazide; excess PhNCS gave also some PhNHCSNHN(CH2CH2C5H4N)CSNHPh (probable structure), m. 180.5-1.0°. I and Me2CO gave the isopropylidene derivative, b15 146-7°, n20D 1.5315, d20 1.011 (dipicrate m. 151-2°). I and mesityl oxide in AcOH in 4 hrs. refluxing gave 52.5% 3,5,5-trimethyl-1-[2-(2-pyridyl)ethyl]pyrazoline, b12 153-7°, b4 158-9.5°, n20D 1.5215, d20 1.005 (dipicrate m. 155-6°). Similarly I and AcCH2CO2Et in C6H6 gave after heating finally to 70° 82% 3-methyl-1-[2-(2-pyridyl)ethyl]-5-pyrazolone, m. 126-7°; similarly was prepared the 3-phenyl analog, m. 125-5.5°. I and Et α-butylacetoacetate gave 3-methyl-4-butyl-1-[2-(2-pyridyl)ethyl]pyrazolone, m. 75-6° (after freezing-out of Et2OEtOH); picrate m. 121.5°. I and 3-benzyl-2,4-pentanedione in 5 hrs. on a steam bath gave 89% yellow 3,5-dimethyl-4-benzyl-1-[2-(2-pyridyl)ethyl]pyrazole, b3 189-93°, 1.5690, 1.1961 (dipicrolonate m. 204-5°); similarly I and Ac2CH2 gave 69% 3,5-dimethyl-1-[2-(2-pyridyl)ethyl]pyrazole (II), b2.5 124-6°, 1.5398, 1.1458 (dipicrolonate m. 194-5°). 3-Propyl-2,4-pentanedione similarly gave 3,5-dimethyl-4-propyl-1-[2-(2-pyridyl)ethyl]pyrazole, b3 148-52°, 1.5269, 0.9766 (dipicrolonate m. 218-19°). II in AcOH was heated on a steam bath with 30% H_2O_2 12 hrs. (with addition of fresh peroxide) and gave after evaporation 26% N-oxide, m. 248-9°. To a solution of Na in PhNHNH2 prepared at 96°, was added 2-vinylpyridine and after 6 hrs. gave after quenching in ice 83.8% 2-[2-(1-phenylhydrazino)ethyl]pyridine, b3.5 185-90°, 1.6105, (picrate m. 100-1°). This kept 1 day with 1-methyl-4-piperidone, then heated briefly, treated with alc. HCl, heated to boiling, and cooled overnight gave 95% 9-[2-(2-pyridyl)ethyl]-3-methyl-1,2,3,4-tetrahydrocarboline, m. 93-3.5°; HCl salt m. 190°; sulfate m. 150°. PhNHNH2 and 2-vinylpyridine in 6:100 AcOH 20 hrs. at reflux gave after addition of KOH and extraction with CHCl3-(CH2Cl)2 29.3% 2-[2-(2-phenylhydrazino)ethyl]pyridine, b3.5 159-63°, m. 122-3° (crude), m. 124.5-5° (from MeOH), along with a glassy substance, b3 180-215°; when the reaction above was run in more concentrated aqueous AcOH, much tar formed. 2-Vinylpyridine added to AcNHNH2 at

120° gave in 6 hrs. 63.5% 2-[2-(2-acetylhydrazino)ethyl]pyridine, b2 173-8° (picrate m. 101-2°). 2-Vinylpyridine added to BzNHNH2 in boiling BuOH and refluxed 1 day and kept 1-2 days gave after dilution with Et2O, a low yield N-benzoyl-N',N'-bis[2-(2-pyridyl)ethyl]hydrazine, m. 137-7.5° (dipicrate m. 174.5-5.0°); the yield was 37% when the refluxing in BuOH extended 20 hrs. and the mixture was concentrated Tetrahydroquinoline and 2-methyl-5-vinylpyridine in the presence of hydroquinone were treated on a steam bath with Na and after 6 hrs. gave 42.6% 2-methyl-5-(N-tetrahydroquinolyl)ethylpyridine, b4 185-6° (picrate m. 199-200°). Similarly, indoline gave only a trace of an oily product, b3 191°; similar reaction in refluxing AcOH in 6 hrs. gave N-acetylindoline, m. 105-6°, only. Ultraviolet spectra of the products are reported.

IT 94311-87-2P, Pyridine, 2-[2-(4-benzyl-3,5-dimethylpyrazol-1-yl)ethyl]- 106278-69-7P, Pyridine, 2-[2-(4-benzyl-3,5-dimethylpyrazol-1-yl)ethyl]-, dipicrolonate
RL: PREP (Preparation)
(preparation of)

RN 94311-87-2 CAPLUS

CN Pyridine, 2-[2-[3,5-dimethyl-4-(phenylmethyl)-1H-pyrazol-1-yl]ethyl]- (CA INDEX NAME)



RN 106278-69-7 CAPLUS

CN Pyridine, 2-[2-[3,5-dimethyl-4-(phenylmethyl)-1H-pyrazol-1-yl]ethyl]-, compd. with 2,4-dihydro-5-methyl-4-nitro-2-(4-nitrophenyl)-3H-pyrazol-3-one (1:2) (CA INDEX NAME)

CM 1

CRN 94311-87-2
CMF C19 H21 N3



CM 2

CRN 550-74-3
CMF C10 H8 N4 O5


NO2
Me
N
N
O2N
O

=>